BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to MCF7 cell line is 3301
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TRPM4 | 17993 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR and Western Blotting and IF staining | Up | 0.76 | 0.0011 | 34680485 |
| CD44 | 1681 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.6 | 1 | 34680485 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs followed by Western Blotting and qRT-PCR | NA | 0.6 | 1 | 29464036 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and qPCR and Western Blotting | NA | 0.6 | 1 | 29846560 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by IF staining and SFA | NA | 0.6 | 1 | 29982992 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IHC staining followed by qRT-PCR | NA | 0.6 | 1 | 30023612 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.6 | 1 | 30188754 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs and Western Blotting followed by SFA | NA | 0.6 | 1 | 35078507 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by Western Blotting | NA | 0.6 | 1 | 33731668 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs followed by SFA and Western Blotting | NA | 0.6 | 1 | 29050299 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Western Blotting | NA | 0.6 | 1 | 29100426 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Western Blotting | NA | 0.6 | 1 | 31672029 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA and IF staining | NA | 0.6 | 1 | 33274565 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA and IF staining | NA | 0.6 | 1 | 35134607 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA and IF staining | NA | 0.6 | 1 | 35413424 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by IHC staining and SFA | NA | 0.6 | 1 | 31579408 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and qRT-PCR | NA | 0.6 | 1 | 34486791 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs and qRT-PCR | NA | 0.6 | 1 | 31762819 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by qRT-PCR and SFA | NA | 0.6 | 1 | 30239174 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA and qRT-PCR | NA | 0.6 | 1 | 31501409 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR followed by FACs and SFA | NA | 0.6 | 1 | 30615901 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and qRT-PCR | NA | 0.6 | 1 | 30188754 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and qRT-PCR | NA | 0.6 | 1 | 31300015 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.6 | 1 | 29243835 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.6 | 1 | 29356693 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Lithium Chloride | Western Blotting and SFA | NA | 0.6 | 1 | 29356693 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Purmorphamine | Western Blotting and SFA | NA | 0.6 | 1 | 29356693 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.6 | 1 | 31497349 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | Western Blotting followed by SFA | NA | 0.6 | 1 | 31690832 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining | NA | 0.6 | 1 | 34718182 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IF staining followed by SFA | NA | 0.6 | 1 | 31591823 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining and Tumorigenicity assay | NA | 0.6 | 1 | 29176652 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and qRT-PCR | NA | 0.6 | 1 | 31728117 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.6 | 1 | 29044153 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.6 | 1 | 29179185 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 34073849 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 35053617 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by CFA | NA | 0.6 | 1 | 35235236 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs followed by SFA | NA | 0.6 | 1 | 33221681 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Carboplatin | FACs followed by SFA | NA | 0.6 | 1 | 33221681 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | FACs followed by SFA | NA | 0.6 | 1 | 33221681 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 33919234 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 34217266 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 34315857 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adriamycin | FACs followed by SFA | NA | 0.6 | 1 | 34403222 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 35205696 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 35254725 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 35508987 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | MACs followed by SFA | NA | 0.6 | 1 | 34715882 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | MACs followed by SFA | NA | 0.6 | 1 | 35109743 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs | NA | 0.6 | 1 | 33262438 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs | NA | 0.6 | 1 | 34234874 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 33305893 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 33419140 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 33511560 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 33603536 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adriamycin | SFA followed by FACs | NA | 0.6 | 1 | 33866606 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 33940518 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 34249423 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 34680485 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 34830821 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 34884742 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 35047440 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by MACs | NA | 0.6 | 1 | 34803458 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | CFA followed by FACs | NA | 0.6 | 1 | 28839461 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs | NA | 0.6 | 1 | 29028589 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 29323439 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 29422957 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 29509055 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 29526821 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs | NA | 0.6 | 1 | 29635751 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 29848346 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 30206184 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 30233203 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Radiotherapy | FACs | NA | 0.6 | 1 | 30272295 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs | NA | 0.6 | 1 | 31286834 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 31286834 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs | NA | 0.6 | 1 | 31627418 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | FACs | NA | 0.6 | 1 | 31627418 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.6 | 1 | 31781916 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs and SFA | NA | 0.6 | 1 | 29185119 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by CFA | NA | 0.6 | 1 | 18681906 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 28725489 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | MK-0752 | FACs followed by SFA | NA | 0.6 | 1 | 29027990 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | RO49097 | FACs followed by SFA | NA | 0.6 | 1 | 29027990 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 29048610 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 29073103 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 29218545 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 29229606 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 29355544 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 29601799 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 29602199 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs followed by SFA | NA | 0.6 | 1 | 29750424 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 29797562 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 30076320 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 30335523 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 30442981 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 30450766 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 31283068 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 31296961 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 31599500 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 31695364 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 31695775 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 31695775 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.6 | 1 | 31736268 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Fulvestrant | FACs followed by SFA | NA | 0.6 | 1 | 31756890 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA and SP assay | NA | 0.6 | 1 | 27974826 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | MACs | NA | 0.6 | 1 | 30482232 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and CFA followed by MACs | NA | 0.6 | 1 | 29187905 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 21062983 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 28003747 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | SFA followed by FACs | NA | 0.6 | 1 | 28718813 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 28823831 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 28930649 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29088759 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29093680 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29187406 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29221160 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29228728 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | SFA followed by FACs | NA | 0.6 | 1 | 29301415 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by FACs | NA | 0.6 | 1 | 29363524 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29746865 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29749438 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Fructose | SFA followed by FACs | NA | 0.6 | 1 | 29796188 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29923726 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 29976159 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adrimycin | SFA followed by FACs | NA | 0.6 | 1 | 30055109 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 30170097 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 30188754 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 30238818 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 30579251 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 30628646 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 31273952 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 31308814 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 31452727 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 31579408 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 31658701 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 31726667 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.6 | 1 | 31756890 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and SP assay | NA | 0.6 | 1 | 31604679 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.6 | 1 | 28938607 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | SFA followed by SP assay and FACs | NA | 0.6 | 1 | 31756890 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Fulvestrant | SFA followed by SP assay and FACs | NA | 0.6 | 1 | 31756890 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Leptin | SFA followed by SP assay and FACs | NA | 0.6 | 1 | 31756890 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by SP assay and FACs | NA | 0.6 | 1 | 31756890 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by FACs | NA | 0.6 | 1 | 18466993 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.6 | 1 | 17881900 |
| CD44 | 1681 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.6 | 1 | 18506619 |
| IKBKE | 14552 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and Western Blotting followed by FACs and SFA | NA | 0.6 | 0.0021 | 30615901 |
| IL6 | 6018 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and ELISA assay | NA | 0.56 | 0.0191 | 31497349 |
| IL6 | 6018 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | MK-0752 | Western Blotting followed by SFA | NA | 0.56 | 0.0191 | 29027990 |
| IL6 | 6018 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | RO49097 | Western Blotting followed by SFA | NA | 0.56 | 0.0191 | 29027990 |
| EXT1 | 3512 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.52 | 0.0032 | 17911267 |
| NANOG | 20857 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | DIM | Single-cell time-of-flight mass cytometry | Up | 0.52 | 0.5461 | 34464674 |
| POU5F1 | 9221 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | DIM | Single-cell time-of-flight mass cytometry | Up | 0.52 | 0.6448 | 34464674 |
| SOX2 | 11195 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Up | 0.52 | 0.5695 | 31289135 |
| SOX2 | 11195 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | DIM | Single-cell time-of-flight mass cytometry | Up | 0.52 | 0.5695 | 34464674 |
| SOX2 | 11195 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.5695 | 34680485 |
| SOX2 | 11195 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.52 | 0.5695 | 17911267 |
| EXT1 | 3512 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Transcriptomics followed by qRT-PCR and Western Blotting | Up | 0.52 | 0.0032 | 29050299 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | CFA followed by IF staining and Western Blotting | NA | 0.52 | 0.684 | 28839461 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adriamycin | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.684 | 33866606 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.684 | 34249423 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA and qRT-PCR | NA | 0.52 | 0.684 | 34528694 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and Western Blotting followed by SFA | NA | 0.52 | 0.684 | 30541574 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IHC staining followed by qRT-PCR | NA | 0.52 | 0.684 | 30023612 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.684 | 30188754 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay and Western Blotting | NA | 0.52 | 0.684 | 35004266 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA and Western Blotting | NA | 0.52 | 0.684 | 29923726 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay and Western Blotting | NA | 0.52 | 0.684 | 31497349 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay and IF staining | NA | 0.52 | 0.684 | 28935760 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | ALDEFLUOR assay followed by qRT-PCR and SFA | NA | 0.52 | 0.684 | 30622340 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | ALDEFLUOR assay followed by SFA and qRT-PCR | NA | 0.52 | 0.684 | 31756890 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.684 | 33305893 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.684 | 34830821 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.684 | 35078507 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.684 | 29243835 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.684 | 29356693 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.684 | 30080291 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.684 | 31501409 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.684 | 31695775 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.684 | 31760908 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting | NA | 0.52 | 0.684 | 31286834 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.684 | 29869379 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.684 | 31283068 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | Western Blotting followed by SFA | NA | 0.52 | 0.684 | 31690832 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining | NA | 0.52 | 0.684 | 34718182 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining | NA | 0.52 | 0.684 | 35134607 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IF staining followed by SFA | NA | 0.52 | 0.684 | 31591823 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IF staining followed by SFA | NA | 0.52 | 0.684 | 31595560 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay and FACs | NA | 0.52 | 0.684 | 31658701 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IHC staining | NA | 0.52 | 0.684 | 30627418 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.52 | 0.684 | 33634797 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.684 | 33603536 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.684 | 34680485 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | qRT-PCR | NA | 0.52 | 0.684 | 31628941 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.684 | 30239174 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and qRT-PCR | NA | 0.52 | 0.684 | 31728117 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.684 | 29179185 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.684 | 30188754 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.684 | 31693936 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.684 | 30579251 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay and SFA | NA | 0.52 | 0.684 | 34298877 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 33791297 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 34315857 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adriamycin | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 34403222 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 35508987 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.52 | 0.684 | 34073849 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and ALDEFLUOR assay | NA | 0.52 | 0.684 | 34234874 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 33940518 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 35047440 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDREFLUOR assay | NA | 0.52 | 0.684 | 33419140 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay | NA | 0.52 | 0.684 | 19190339 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay | NA | 0.52 | 0.684 | 30478301 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay and SFA | NA | 0.52 | 0.684 | 31296961 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 28802057 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 29027990 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 29050299 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 29229606 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 29679903 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 30206184 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 30214607 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 30450766 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 31756890 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | ALDEFLUOR assay followed by SFA | NA | 0.52 | 0.684 | 31760402 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | ALDEFLUOR assay followed by SFA and SP assay | NA | 0.52 | 0.684 | 27974826 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.52 | 0.684 | 31666201 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.52 | 0.684 | 29434914 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.52 | 0.684 | 29602199 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.52 | 0.684 | 30335523 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and CFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 29187905 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 21062983 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 28823831 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 28930649 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 29093680 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 29348189 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 29363524 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 29383157 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Fructose | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 29796188 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 29964299 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 30032164 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by ALDEFLUOR assay | NA | 0.52 | 0.684 | 31308814 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.52 | 0.684 | 30242135 |
| ALDH1A1 | 402 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.52 | 0.684 | 31726667 |
| BMI1 | 1066 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 0.1135 | 29982992 |
| BMI1 | 1066 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.1135 | 31308814 |
| BMI1 | 1066 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.1135 | 31672029 |
| BMI1 | 1066 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.1135 | 34486791 |
| GJA3 | 4277 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 0.0011 | 34830485 |
| GPT2 | 18062 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | CFA followed by IF staining and Western Blotting | NA | 0.52 | 0.0011 | 28839461 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 0.5461 | 29982992 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and Western Blotting followed by CFA | NA | 0.52 | 0.5461 | 35235236 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adriamycin | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5461 | 33866606 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5461 | 34052833 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5461 | 34249423 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5461 | 34755264 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by qRT-PCR and SFA | NA | 0.52 | 0.5461 | 33791297 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.52 | 0.5461 | 31736268 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5461 | 31300015 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5461 | 31760402 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.5461 | 28703799 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and RT-PCR followed by SFA | NA | 0.52 | 0.5461 | 29601799 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.5461 | 30188754 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.5461 | 30188754 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by SP assay and Western Blotting | NA | 0.52 | 0.5461 | 35004266 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 33305893 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 33419140 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 34830821 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5461 | 35078507 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | CFA followed by Western Blotting | NA | 0.52 | 0.5461 | 28839461 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 28802057 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 28823831 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 29243835 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 29356693 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 29797562 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 31501409 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 31604679 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 31695775 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5461 | 31760908 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5461 | 29287960 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Lithium Chloride | Western Blotting and SFA | NA | 0.52 | 0.5461 | 29356693 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Purmorphamine | Western Blotting and SFA | NA | 0.52 | 0.5461 | 29356693 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5461 | 29956731 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5461 | 29956731 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5461 | 30482236 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.5461 | 30335523 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.52 | 0.5461 | 31584203 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.5461 | 34217266 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.5461 | 34298877 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5461 | 33511560 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5461 | 34486791 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5461 | 34803458 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR | NA | 0.52 | 0.5461 | 31762819 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | MK-0752 | qRT-PCR followed by SFA | NA | 0.52 | 0.5461 | 29027990 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR | NA | 0.52 | 0.5461 | 30615901 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5461 | 30175027 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | SFA followed by qRT-PCR | NA | 0.52 | 0.5461 | 30340507 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5461 | 30628646 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5461 | 31693936 |
| NANOG | 20857 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5461 | 30579251 |
| NFE2L2 | 7782 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and IHC staining | NA | 0.52 | 0.0042 | 31672029 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and IF staining | NA | 0.52 | 0.6448 | 29100426 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and IHC staining | NA | 0.52 | 0.6448 | 29749438 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and Western Blotting followed by CFA | NA | 0.52 | 0.6448 | 35235236 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 34052833 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 34249423 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 35029026 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by qRT-PCR and SFA | NA | 0.52 | 0.6448 | 33791297 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.52 | 0.6448 | 31736268 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 31300015 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 31760402 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and RT-PCR | NA | 0.52 | 0.6448 | 29511337 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and RT-PCR followed by SFA | NA | 0.52 | 0.6448 | 29601799 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qPCR and IF staining | NA | 0.52 | 0.6448 | 29846560 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.6448 | 30188754 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.6448 | 30188754 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.52 | 0.6448 | 33731668 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 33305893 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.6448 | 34362383 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 34528694 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | CFA followed by Western Blotting | NA | 0.52 | 0.6448 | 28839461 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 28802057 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 28823831 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29106390 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29243835 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29356693 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29750424 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29797562 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 30080291 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 30450766 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31501409 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31604679 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31695775 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting | NA | 0.52 | 0.6448 | 31286834 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting and SFA | NA | 0.52 | 0.6448 | 29185119 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.6448 | 29287960 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.6448 | 30482236 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 29218545 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 30335523 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 31584203 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.52 | 0.6448 | 33634797 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.6448 | 34217266 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.6448 | 34298877 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR followed by SFA | NA | 0.52 | 0.6448 | 34830485 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 33511560 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34486791 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34803458 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR | NA | 0.52 | 0.6448 | 31762819 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.6448 | 30239174 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | MK-0752 | qRT-PCR followed by SFA | NA | 0.52 | 0.6448 | 29027990 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR followed by SFA | NA | 0.52 | 0.6448 | 30214607 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and qRT-PCR | NA | 0.52 | 0.6448 | 31728117 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29044153 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 30175027 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 30340507 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 30628646 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 31693936 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 30579251 |
| POU5F1 | 9221 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.52 | 0.6448 | 29509055 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 0.5695 | 29982992 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and Western Blotting followed by CFA | NA | 0.52 | 0.5695 | 35235236 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adriamycin | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 33866606 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 34755264 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by qRT-PCR and SFA | NA | 0.52 | 0.5695 | 33791297 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.52 | 0.5695 | 31736268 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qPCR and Western Blotting | NA | 0.52 | 0.5695 | 29846560 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 30622340 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 30622340 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 31300015 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 31760402 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 28703799 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and RT-PCR followed by SFA | NA | 0.52 | 0.5695 | 29601799 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.5695 | 30188754 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.5695 | 30188754 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.52 | 0.5695 | 33731668 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 33305893 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 33419140 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 34830821 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5695 | 34362383 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 34528694 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | CFA followed by Western Blotting | NA | 0.52 | 0.5695 | 28839461 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 28802057 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 28823831 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29100426 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29383157 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29434914 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29749438 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29797562 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 30080291 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31308814 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31501409 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31604679 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31672029 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31695775 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31760908 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting | NA | 0.52 | 0.5695 | 31286834 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting | NA | 0.52 | 0.5695 | 31591207 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5695 | 29287960 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5695 | 29956731 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.52 | 0.5695 | 30482236 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 29218545 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 30335523 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 31584203 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 31690832 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.52 | 0.5695 | 33634797 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 34217266 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 34298877 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR followed by SFA | NA | 0.52 | 0.5695 | 34830485 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 33511560 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34486791 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34680485 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34803458 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 35029026 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 30239174 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | MK-0752 | qRT-PCR followed by SFA | NA | 0.52 | 0.5695 | 29027990 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR | NA | 0.52 | 0.5695 | 30206184 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | RT-PCR followed by SFA | NA | 0.52 | 0.5695 | 28929082 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 29044153 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 30175027 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 30628646 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 30579251 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.52 | 0.5695 | 29509055 |
| SOX2 | 11195 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.52 | 0.5695 | 29048610 |
| ABCG2 | 74 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Up | 0.48 | 0.1739 | 31289135 |
| CXCR4 | 2561 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.48 | 0.0498 | 34680485 |
| CXCR4 | 2561 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.0498 | 19353633 |
| CXCR4 | 2561 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.0498 | 31501409 |
| ETV4 | 3493 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.48 | 0.0032 | 34680485 |
| MYC | 7553 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.48 | 0.1304 | 34680485 |
| NRP1 | 8004 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.48 | 0.0053 | 34680485 |
| PROM1 | 9454 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | DIM | Single-cell time-of-flight mass cytometry | Up | 0.48 | 0.7582 | 34464674 |
| SCD | 10571 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.48 | 0.0127 | 34680485 |
| SCD | 10571 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.0127 | 31501409 |
| SOX9 | 11204 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.48 | 0.0244 | 34680485 |
| ABCG2 | 74 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.48 | 0.1739 | 17911267 |
| ABCB1 | 40 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | qRT-PCR followed by SFA and Western Blotting | NA | 0.48 | 0.0604 | 29050299 |
| ABCB1 | 40 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0604 | 31604679 |
| ABCB1 | 40 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting | NA | 0.48 | 0.0604 | 29028589 |
| ABCB1 | 40 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting | NA | 0.48 | 0.0604 | 29635751 |
| ABCB1 | 40 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | qRT-PCR | NA | 0.48 | 0.0604 | 31628941 |
| ABCB1 | 40 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.0604 | 30188754 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 34249423 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 28935760 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 31604679 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 31695364 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by Western Blotting and SFA | NA | 0.48 | 0.1739 | 30274780 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting | NA | 0.48 | 0.1739 | 29028589 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining | NA | 0.48 | 0.1739 | 34718182 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 34486791 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR | NA | 0.48 | 0.1739 | 31762819 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 29982992 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 30175027 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 30188754 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by FACs | NA | 0.48 | 0.1739 | 18951337 |
| ABCG2 | 74 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.48 | 0.1739 | 17881900 |
| ADORA2B | 264 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and qRT-PCR followed by SFA | NA | 0.48 | 0.0042 | 29218545 |
| ADORA2B | 264 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and FACs | NA | 0.48 | 0.0042 | 30242135 |
| BAG3 | 939 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 28703799 |
| CCND1 | 1582 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0201 | 31595560 |
| CCND1 | 1582 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0201 | 31604679 |
| CCND1 | 1582 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0201 | 31604679 |
| CCND1 | 1582 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.0201 | 29982992 |
| CD47 | 1682 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 31273952 |
| CXCR4 | 2561 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0498 | 28703799 |
| CXCR4 | 2561 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0498 | 34052833 |
| CXCR4 | 2561 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by Western Blotting and SFA | NA | 0.48 | 0.0498 | 30274780 |
| CXCR4 | 2561 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.0498 | 34680485 |
| EGFR | 3236 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0074 | 29464036 |
| ERBB2 | 3430 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0074 | 29464036 |
| ETV4 | 3493 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 34052833 |
| FADS2 | 3575 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0064 | 34486791 |
| FAS | 11920 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 34486791 |
| HSPA9 | 5244 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 34249423 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by qRT-PCR and SFA | NA | 0.48 | 0.0891 | 33791297 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0891 | 31595560 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0891 | 33305893 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0891 | 33419140 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting | NA | 0.48 | 0.0891 | 31591207 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting and SFA | NA | 0.48 | 0.0891 | 29185119 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.48 | 0.0891 | 29287960 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.0891 | 30214607 |
| KLF4 | 6348 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR | NA | 0.48 | 0.0891 | 30615901 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.1304 | 31736268 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 30149665 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 33305893 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.48 | 0.1304 | 35078507 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 29106390 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 29750424 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 30450766 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 31604679 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting and SFA | NA | 0.48 | 0.1304 | 29185119 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.48 | 0.1304 | 29287960 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Lithium Chloride | Western Blotting and SFA | NA | 0.48 | 0.1304 | 29356693 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.1304 | 30335523 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and SFA | NA | 0.48 | 0.1304 | 34298877 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.48 | 0.1304 | 35413424 |
| MYC | 7553 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | SFA followed by qRT-PCR | NA | 0.48 | 0.1304 | 30340507 |
| NFKB1 | 7794 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0064 | 34755264 |
| NFKB1 | 7794 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.0064 | 29846560 |
| NGFR | 7809 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.018 | 34755264 |
| NGFR | 7809 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.48 | 0.018 | 30175027 |
| NRP1 | 8004 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0053 | 29179185 |
| PELP1 | 30134 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.0011 | 29348189 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.7582 | 31595560 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IHC staining followed by qRT-PCR | NA | 0.48 | 0.7582 | 30023612 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.7582 | 34830821 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.7582 | 29869379 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IF staining and SFA | NA | 0.48 | 0.7582 | 35413424 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Cisplatin | IF staining followed by SFA | NA | 0.48 | 0.7582 | 31595560 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining | NA | 0.48 | 0.7582 | 28935760 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining and Tumorigenicity assay | NA | 0.48 | 0.7582 | 29176652 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.7582 | 29044153 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 29073103 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 29434914 |
| PROM1 | 9454 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and SP assay | NA | 0.48 | 0.7582 | 31604679 |
| SCD | 10571 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0127 | 34486791 |
| SIK2 | 21680 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.0011 | 35277657 |
| SOX9 | 11204 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0244 | 30622340 |
| SOX9 | 11204 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0244 | 30622340 |
| SOX9 | 11204 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | Western Blotting followed by SFA | NA | 0.48 | 0.0244 | 31690832 |
| THRB | 11799 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0021 | 31760908 |
| UBQLN1 | 12508 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by qRT-PCR and Western Blotting and SFA | NA | 0.48 | 0.0021 | 34528694 |
| VEGFA | 12680 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 29179185 |
| WNT1 | 12774 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0074 | 31595560 |
| PGR | 8910 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.44 | 0.0021 | 34680485 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.44 | 0.456 | 30188754 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Western Blotting | NA | 0.44 | 0.456 | 29100426 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Western Blotting | NA | 0.44 | 0.456 | 31672029 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by IHC staining and SFA | NA | 0.44 | 0.456 | 31579408 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by qRT-PCR and SFA | NA | 0.44 | 0.456 | 30239174 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA and qRT-PCR | NA | 0.44 | 0.456 | 31501409 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR followed by FACs and SFA | NA | 0.44 | 0.456 | 30615901 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and qRT-PCR | NA | 0.44 | 0.456 | 30188754 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and qRT-PCR | NA | 0.44 | 0.456 | 31300015 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | CFA followed by FACs | NA | 0.44 | 0.456 | 28839461 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs | NA | 0.44 | 0.456 | 29028589 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 29323439 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 29422957 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 29509055 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 29526821 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs | NA | 0.44 | 0.456 | 29635751 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 29848346 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 30206184 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 30233203 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Radiotherapy | FACs | NA | 0.44 | 0.456 | 30272295 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs | NA | 0.44 | 0.456 | 31286834 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 31286834 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs | NA | 0.44 | 0.456 | 31627418 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | FACs | NA | 0.44 | 0.456 | 31627418 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 31762819 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.44 | 0.456 | 31781916 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs and SFA | NA | 0.44 | 0.456 | 29185119 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by CFA | NA | 0.44 | 0.456 | 18681906 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 28725489 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | MK-0752 | FACs followed by SFA | NA | 0.44 | 0.456 | 29027990 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | RO49097 | FACs followed by SFA | NA | 0.44 | 0.456 | 29027990 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs followed by SFA | NA | 0.44 | 0.456 | 29050299 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 29218545 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 29229606 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 29355544 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 29601799 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 29602199 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 29797562 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 30076320 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 30335523 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 30442981 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 30450766 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 31283068 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 31296961 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 31599500 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 31695364 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 31695775 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 31695775 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 31736268 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs followed by SFA | NA | 0.44 | 0.456 | 31756890 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA and SP assay | NA | 0.44 | 0.456 | 27974826 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | MACs | NA | 0.44 | 0.456 | 30482232 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and CFA followed by MACs | NA | 0.44 | 0.456 | 29187905 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 21062983 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 28003747 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Paclitaxel | SFA followed by FACs | NA | 0.44 | 0.456 | 28718813 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 28823831 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 28930649 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29088759 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29093680 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29187406 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29221160 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29228728 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | SFA followed by FACs | NA | 0.44 | 0.456 | 29301415 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by FACs | NA | 0.44 | 0.456 | 29363524 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29464036 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29746865 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29749438 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Fructose | SFA followed by FACs | NA | 0.44 | 0.456 | 29796188 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29846560 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29923726 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 29976159 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adrimycin | SFA followed by FACs | NA | 0.44 | 0.456 | 30055109 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 30170097 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 30188754 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 30238818 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 30579251 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 30628646 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 31273952 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 31308814 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 31452727 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 31579408 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 31658701 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 31726667 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 31756890 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.44 | 0.456 | 28938607 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | SFA followed by SP assay and FACs | NA | 0.44 | 0.456 | 31756890 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Fulvestrant | SFA followed by SP assay and FACs | NA | 0.44 | 0.456 | 31756890 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Leptin | SFA followed by SP assay and FACs | NA | 0.44 | 0.456 | 31756890 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by SP assay and FACs | NA | 0.44 | 0.456 | 31756890 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by FACs | NA | 0.44 | 0.456 | 18466993 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.44 | 0.456 | 17881900 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.44 | 0.456 | 18506619 |
| MIR5188 | 43502 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and IF staining followed by SFA and Migration assay | NA | 0.44 | 0.0011 | 31604679 |
| MIR655 | 32911 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and IF staining followed by SFA and Migration Invasion assay | NA | 0.44 | 0.0011 | 29321644 |
| PGR | 8910 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and IHC staining | Down | 0.44 | 0.0021 | 19353633 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by Western Blotting | NA | 0.4 | 0.456 | 33731668 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA and IF staining | NA | 0.4 | 0.456 | 33274565 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.4 | 0.456 | 31497349 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining | NA | 0.4 | 0.456 | 34718182 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.4 | 0.456 | 34073849 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.4 | 0.456 | 35053617 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs and SFA | NA | 0.4 | 0.456 | 35078507 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by CFA | NA | 0.4 | 0.456 | 35235236 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 33919234 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 34217266 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 34315857 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adriamycin | FACs followed by SFA | NA | 0.4 | 0.456 | 34403222 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 35134607 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 35205696 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 35254725 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 35413424 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 35508987 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | MACs followed by SFA | NA | 0.4 | 0.456 | 34715882 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | MACs followed by SFA | NA | 0.4 | 0.456 | 35109743 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs | NA | 0.4 | 0.456 | 33262438 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs | NA | 0.4 | 0.456 | 34234874 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 33305893 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 33419140 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 33511560 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 33603536 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Adriamycin | SFA followed by FACs | NA | 0.4 | 0.456 | 33866606 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 33940518 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 34249423 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 34486791 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 34680485 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 34830821 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 34884742 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 35047440 |
| CD24 | 1645 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by MACs | NA | 0.4 | 0.456 | 34803458 |
| MAP2K1 | 6840 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0021 | 17911267 |
| STAT3 | 11364 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0223 | 17911267 |
| STAT3 | 11364 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.36 | 0.0223 | 34680485 |
| CTAG1B | 2491 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by IF staining and SFA | NA | 0.36 | 0.0011 | 31579408 |
| CTAG1B | 2491 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by IHC staining and SFA | NA | 0.36 | 0.0011 | 31579408 |
| STAT3 | 11364 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.36 | 0.0223 | 31619923 |
| STAT3 | 11364 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Tamoxifen | SFA followed by Western Blotting | NA | 0.36 | 0.0223 | 31760402 |
| STAT3 | 11364 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.36 | 0.0223 | 30214607 |
| STAT3 | 11364 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | FACs followed by Migration assay | NA | 0.36 | 0.0223 | 31286834 |
| FXYD3 | 4027 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and RT-PCR | NA | 0.32 | 0.0053 | 30206184 |
| LUCAT1 | 48498 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and FACs | NA | 0.32 | 0.0021 | 31300015 |
| CEBPD | 1835 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0042 | 31501409 |
| HIF1A | 4910 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0106 | 31501409 |
| SHH | 10848 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.28 | 0.0201 | 34680485 |
| SNAI2 | 11094 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.28 | 0.0159 | 34680485 |
| SNAI2 | 11094 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0159 | 31501409 |
| TENM4 | 29945 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.28 | 0.0021 | 34680485 |
| VIM | 12692 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Up | 0.28 | 0.017 | 31289135 |
| SNAI2 | 11094 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.28 | 0.0159 | 31666201 |
| ABCC1 | 51 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting | NA | 0.28 | 0.0212 | 29028589 |
| ABCC1 | 51 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0212 | 30175027 |
| AKT1 | 391 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0074 | 29088759 |
| AKT1 | 391 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0074 | 31308814 |
| BGN | 1044 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.28 | 0.0032 | 35053617 |
| CEBPD | 1835 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0042 | 30262865 |
| CTNNB1 | 2514 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 29100426 |
| CTNNB1 | 2514 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 31604679 |
| CTNNB1 | 2514 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Lithium Chloride | Western Blotting and SFA | NA | 0.28 | 0.0647 | 29356693 |
| CTNNB1 | 2514 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by IF staining | NA | 0.28 | 0.0647 | 33511560 |
| DDX27 | 15837 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0011 | 34362383 |
| EPCAM | 11529 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.28 | 0.211 | 31584203 |
| EPCAM | 11529 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.28 | 0.211 | 35413424 |
| EPCAM | 11529 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs | NA | 0.28 | 0.211 | 34073849 |
| EPCAM | 11529 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 33511560 |
| EPCAM | 11529 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 21062983 |
| EPCAM | 11529 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 29088759 |
| EPCAM | 11529 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 31452727 |
| EPCAM | 11529 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.28 | 0.211 | 17881900 |
| GCLC | 4311 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 31672029 |
| GLI1 | 4317 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0308 | 34052833 |
| GLI1 | 4317 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qPCR | NA | 0.28 | 0.0308 | 29846560 |
| HIF1A | 4910 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0106 | 34830821 |
| HIF1A | 4910 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0106 | 31308814 |
| HSF1 | 5224 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 29088759 |
| JUN | 6204 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 31604679 |
| JUN | 6204 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.28 | 0.0053 | 35413424 |
| KBM1A | NA | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0011 | 31627418 |
| LIN28A | 15986 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0138 | 29106390 |
| LIN28A | 15986 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.28 | 0.0138 | 28938607 |
| LIN28B | 32207 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 34052833 |
| LINC00511 | 43564 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Western Blotting and SFA | NA | 0.28 | 0.0011 | 30482236 |
| NOTCH1 | 7881 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and Western Blotting | NA | 0.28 | 0.0477 | 33262438 |
| NOTCH1 | 7881 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IF staining followed by SFA | NA | 0.28 | 0.0477 | 31595560 |
| NOTCH1 | 7881 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Lapatinib | RT-PCR | NA | 0.28 | 0.0477 | 29895705 |
| NOTCH2 | 7882 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0117 | 29100426 |
| PAK1 | 8590 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 31658701 |
| PDK1 | 8809 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 29106390 |
| PDK1 | 8809 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0053 | 34052833 |
| PRMT5 | 10894 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting and SFA | NA | 0.28 | 0.0021 | 29185119 |
| PTBP3 | 10253 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and Migartion Invasion assay | NA | 0.28 | 0.0011 | 29187406 |
| RELA | 9955 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 31497349 |
| SHH | 10848 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 34052833 |
| SHH | 10848 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qPCR | NA | 0.28 | 0.0201 | 29846560 |
| SNAI2 | 11094 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0159 | 31604679 |
| SRC | 11283 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 34830821 |
| TENM4 | 29945 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 33672732 |
| TMCC3 | 29199 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 33742122 |
| USP37 | 20063 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting and Migartion Invasion assay | NA | 0.28 | 0.0011 | 30482232 |
| VCP | 12666 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.28 | 0.0042 | 33731668 |
| VIM | 12692 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.017 | 31604679 |
| VIM | 12692 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.017 | 33603536 |
| YAP1 | 16262 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Doxorubicin | Western Blotting | NA | 0.28 | 0.0117 | 29635751 |
| ACTA2 | 130 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Up | 0.24 | 0.0011 | 31289135 |
| ALOX5 | 435 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0021 | 34680485 |
| CAV1 | 1527 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Up | 0.24 | 0.0117 | 31289135 |
| CAV1 | 1527 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0117 | 31501409 |
| CAV2 | 1528 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Up | 0.24 | 0.0074 | 31289135 |
| CAV2 | 1528 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0074 | 34680485 |
| CAV2 | 1528 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0074 | 31501409 |
| CCNA2 | 1578 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Down | 0.24 | 0.0042 | 31289135 |
| CCNA2 | 1578 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0042 | 34680485 |
| CCNB1 | 1579 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Down | 0.24 | 0.0053 | 31289135 |
| CCNB1 | 1579 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0053 | 19353633 |
| CDH1 | 1748 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Down | 0.24 | 0.0053 | 31289135 |
| CHEK1 | 1925 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Down | 0.24 | 0.0011 | 31289135 |
| DHRS3 | 17693 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0032 | 31501409 |
| LEF1 | 6551 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Up | 0.24 | 0.0032 | 31289135 |
| MIR18A | 31548 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 30188754 |
| MIR18A | 31548 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0021 | 30188754 |
| MIR19A | 31574 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0064 | 30188754 |
| MIR19A | 31574 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0064 | 30188754 |
| MIR27A | 31613 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 30188754 |
| MIR27A | 31613 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0053 | 29187905 |
| MIR27A | 31613 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0053 | 30188754 |
| MIR27A | 31613 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0053 | 30188754 |
| MIR29A | 31616 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0053 | 29187905 |
| MIR29A | 31616 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0053 | 30188754 |
| MIR29A | 31616 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0053 | 30188754 |
| MIR3605 | 38922 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 30188754 |
| MIR3912 | 38923 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 30188754 |
| MIR6516 | 50233 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 30188754 |
| MKI67 | 7107 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Down | 0.24 | 0.0021 | 31289135 |
| PHLDA1 | 8933 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0042 | 31501409 |
| PTPRE | 9669 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0032 | 34680485 |
| RHOBTB3 | 18757 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0032 | 31501409 |
| SNAI1 | 11128 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0212 | 34680485 |
| STC2 | 11374 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 34680485 |
| STUB1 | 11427 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29511337 |
| SULF1 | 20391 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 34680485 |
| TBX3 | 11602 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Down | 0.24 | 0.0032 | 31289135 |
| TGFB1 | 11766 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0138 | 34680485 |
| TGFB2 | 11768 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Docetaxel | Transcriptomics followed by qRT-PCR | Up | 0.24 | 0.0074 | 31289135 |
| TGFB2 | 11768 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0074 | 34680485 |
| TM4SF1 | 11853 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 34680485 |
| TNFRSF11B | 11909 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 34680485 |
| ALOX5 | 435 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0021 | 31666201 |
| BAMBI | 30251 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 34680485 |
| BMP7 | 1074 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 34680485 |
| C16ORF46 | 26525 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 17911267 |
| CAV1 | 1527 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0117 | 34680485 |
| CYCS | 19986 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 17911267 |
| DHRS3 | 17693 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 34680485 |
| DUSP16 | 17909 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 17911267 |
| EGR4 | 3241 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0011 | 31666201 |
| ENC1 | 3345 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 34680485 |
| FAXDC2 | 1334 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 34680485 |
| KCNE4 | 6244 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 34680485 |
| KRT20 | 20412 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 34680485 |
| LRP8 | 6700 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 17911267 |
| MAOB | 6834 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 34680485 |
| MIR210 | 31587 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0064 | 30188754 |
| NLK | 29858 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 17911267 |
| PHLDA1 | 8933 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 34680485 |
| PIAS2 | 17311 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 17911267 |
| PIK3C2A | 8971 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 17911267 |
| PPP3R1 | 9317 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 17911267 |
| PTPRE | 9669 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0032 | 31666201 |
| RHOBTB3 | 18757 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 34680485 |
| SNAI1 | 11128 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0212 | 31666201 |
| SOS1 | 11187 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 17911267 |
| SOS2 | 11188 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 17911267 |
| SPARC | 11219 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0042 | 31666201 |
| SYNJ1 | 11503 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 17911267 |
| TGFB2 | 11768 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0074 | 31666201 |
| TGM2 | 11778 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 34680485 |
| UGDH | 12525 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0053 | 34680485 |
| NUMB | 8060 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | IF staining followed by SFA | NA | 0.24 | 0.0021 | 31595560 |
| TGFB2 | 11768 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.24 | 0.0074 | 35413424 |
| ABCC2 | 53 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0106 | 34680485 |
| ALDH1A3 | 409 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0201 | 34680485 |
| CASC15 | 28245 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0021 | 34680485 |
| DDIT3 | 2726 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0032 | 19353633 |
| FN1 | 3778 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0053 | 34680485 |
| GDF15 | 30142 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0042 | 34680485 |
| GDF15 | 30142 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0042 | 31501409 |
| HMOX1 | 5013 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 34680485 |
| HMOX1 | 5013 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0064 | 31501409 |
| HSPA5 | 5238 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0117 | 31501409 |
| INHBB | 6067 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0064 | 34680485 |
| ITGA6 | 6142 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0265 | 34680485 |
| MET | 7029 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.2 | 0.0191 | 31501409 |
| ABCC2 | 53 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0106 | 30175027 |
| ALDH1A2 | 15472 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0117 | 34486791 |
| ALDH1A3 | 409 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR | NA | 0.2 | 0.0201 | 30615901 |
| ATF4 | 786 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by RT-PCR | NA | 0.2 | 0.0011 | 29601799 |
| ATF6 | 791 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by RT-PCR | NA | 0.2 | 0.0011 | 29601799 |
| BCL2 | 990 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 33603536 |
| CASC15 | 28245 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 35235236 |
| DDIT3 | 2726 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by RT-PCR | NA | 0.2 | 0.0032 | 29601799 |
| DNMT1 | 2976 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 29044153 |
| EIF2AK3 | 3255 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by RT-PCR | NA | 0.2 | 0.0011 | 29601799 |
| ERN1 | 3449 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by RT-PCR | NA | 0.2 | 0.0021 | 29601799 |
| ESR1 | 3467 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 19353633 |
| ETV1 | 3490 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 34052833 |
| FEZF1-AS1 | 41001 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and RT-PCR followed by Migration assay | NA | 0.2 | 0.0021 | 29797562 |
| FGFR3 | 3690 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.2 | 0.0011 | 35413424 |
| FGFR4 | 3691 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.2 | 0.0021 | 35413424 |
| FN1 | 3778 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 34486791 |
| FOXD2-AS1 | 44256 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 30628646 |
| GDF15 | 30142 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 34486791 |
| HMGA2 | 5009 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.2 | 0.0042 | 35413424 |
| HMOX1 | 5013 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0064 | 30238818 |
| HSPA5 | 5238 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by RT-PCR | NA | 0.2 | 0.0117 | 29601799 |
| INHBB | 6067 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.2 | 0.0064 | 35413424 |
| ITGA6 | 6142 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.2 | 0.0265 | 33634797 |
| ITGA6 | 6142 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and SFA followed by FACs and qRT-PCR | NA | 0.2 | 0.0265 | 17935134 |
| ITGA6 | 6142 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.2 | 0.0265 | 17881900 |
| LncCCAT1 | NA | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR and SFA and Migration Invasion assay | NA | 0.2 | 0.0011 | 31695775 |
| LncCCAT1 | NA | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFAand Migration assay | NA | 0.2 | 0.0011 | 31695775 |
| MET | 7029 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | RT-PCR and SFA | NA | 0.2 | 0.0191 | 35413424 |
| MIR181A1 | 31590 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 35029026 |
| NES | 7756 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.2 | 0.0573 | 33634797 |
| PiRNA-823 | NA | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs for CSC marker followed by qRT-PCR and SFA | NA | 0.2 | 0.0011 | 33791297 |
| S1PR3 | 3167 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 33919234 |
| SPRY4?IT1 | 42394 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 31736268 |
| KIT | 6342 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.12 | 0.018 | 34680485 |
| MCAM | 6934 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.12 | 0.0064 | 34680485 |
| ATXN1 | 10548 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.12 | 0.0064 | 17881900 |
| BCRP1 | 39073 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay followed by SFA and FACs | NA | 0.12 | 0.0011 | 17881900 |
| BMP2 | 1069 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs and SFA followed by Migration Invasion assay | NA | 0.12 | 0.0042 | 28725489 |
| CD70 | 11937 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.12 | 0.0021 | 30175027 |
| JAG1 | 6188 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | Lapatinib | FACs followed by SFA | NA | 0.12 | 0.0117 | 29895705 |
| KIT | 6342 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.12 | 0.018 | 30175027 |
| LIN28A- | 15986 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and CFA followed by MACs | NA | 0.12 | 0.0011 | 29187905 |
| LINC01133 | 49447 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | FACs followed by SFA | NA | 0.12 | 0.0011 | 31283068 |
| MCAM | 6934 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs | NA | 0.12 | 0.0064 | 30175027 |
| MST1 | 7380 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.12 | 0.0032 | 28938607 |
| MST1R | 7381 | LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.12 | 0.0032 | 28938607 |
| A2M | 7 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| ABCA1 | 29 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| ABCA12 | 14637 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ABCA4 | 34 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ABCA7 | 37 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ABCB6 | 47 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ABCC3 | 54 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ABCC4 | 55 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ABCC5 | 56 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| ABCC8 | 59 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ABCG1 | 73 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| ABHD17B | 24278 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| ABHD17C | 26925 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ABHD17C | 26925 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ABHD2 | 18717 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ABHD6 | 21398 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ABI1 | 11320 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ABTB2 | 23842 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| AC013444 | 6469 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| AC068538 | 28860 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| AC073069 | 7506 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| AC073621 | 15828 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ACACB | 85 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ACAD10 | 21597 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ACADM | 89 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ACADSB | 91 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| ACBD3 | 15453 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| ACE | 2707 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ACHE | 108 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ACKR3 | 23692 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ACSF2 | 26101 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| ACSL1 | 3569 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ACSL1 | 3569 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19353633 |
| ACSL3 | 3570 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19353633 |
| ACSS1 | 16091 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ACSS2 | 15814 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ACSS2 | 15814 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ACTG1 | 144 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ACTR3C | 37282 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ADA | 186 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ADAM19 | 197 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ADAM23 | 202 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ADAMTS1 | 217 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| ADAMTS17 | 17109 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ADAMTS9 | 13202 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ADAMTS9 | 13202 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ADAMTSL4 | 19706 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ADAR | 225 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ADAT2 | 21172 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ADCY1 | 232 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| ADCY5 | 236 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ADGRA2 | 17849 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ADGRE2 | 3337 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ADGRG6 | 13841 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| ADGRG7 | 19241 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ADH7 | 256 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ADIRF | 24043 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ADORA1 | 262 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ADRA2A | 281 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| AFAP1 | 24017 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| AFAP1L2 | 25901 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| AFF1 | 7135 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| AFF4 | 17869 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| AGAP11 | 29421 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| AGR3 | 24167 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| AGTR1 | 336 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| AHNAK | 347 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| AHRR | 346 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| AIF1L | 28904 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| AJM1 | 37284 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| AJUBA | 20250 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| AKAP12 | 370 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| AKAP13 | 371 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| AKNA | 24108 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| AKR1B1 | 381 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| AKR1C2 | 385 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 17911267 |
| ALCAM | 400 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0583 | 34680485 |
| ALCAM | 400 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0583 | 17911267 |
| ALDH3A1 | 405 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 34680485 |
| ALDH3B2 | 411 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ALOX12B | 430 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ALPK2 | 20565 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| AMIGO3 | 24075 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| AMOT | 17810 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| AMZ1 | 22231 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ANG | 483 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ANGPTL4 | 16039 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ANK1 | 492 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| ANKDD1A | 28002 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ANKH | 15492 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ANKRD18B | 23644 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ANKRD27 | 25310 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ANKRD34A | 27639 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ANKRD34B | 33736 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ANKRD35 | 26323 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ANKRD50 | 29223 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| ANKS1B | 24600 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ANO7 | 31677 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ANOS1 | 6211 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ANXA2 | 537 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| ANXA3 | 541 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0085 | 34680485 |
| ANXA8 | 546 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| ANXA9 | 547 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| AOX1 | 553 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| AOX1 | 553 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| AP3B2 | 567 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| APBA1 | 578 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| APH1B | 24080 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| APLP1 | 597 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| APOD | 612 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| APOE | 613 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| APP | 620 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| AQP2 | 634 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| AQP3 | 636 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| AQP6 | 639 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ARC | 648 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| AREG | 651 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 34680485 |
| AREG | 651 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| ARF4 | 655 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ARFGEF1 | 15772 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| ARFGEF3 | 21213 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ARHGAP1 | 673 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| ARHGAP18 | 21035 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ARHGAP21 | 23725 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ARHGAP26 | 17073 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ARHGAP36 | 26388 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ARHGAP5-AS1 | 20279 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ARHGDIG | 680 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ARHGEF3 | 683 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| ARHGEF37 | 34430 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ARID2 | 18037 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ARID5A | 17361 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ARID5A | 17361 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| ARID5B | 17362 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ARL4A | 695 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ARMT1 | 17872 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ARNT2 | 16876 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ARSA | 713 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ASB9 | 17184 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ASIC1 | 100 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ASNS | 753 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| ASRGL1 | 16448 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| ASS1 | 758 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ASS1 | 758 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| ASTN2 | 17021 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ATG16L2 | 25464 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ATOH8 | 24126 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ATP13A4 | 25422 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ATP1B1 | 804 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ATP2A3 | 813 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ATP2B1-AS1 | 27883 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ATP2C2 | 29103 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ATP5F1C | 833 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ATP6AP1 | 868 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ATP6V0A4 | 866 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ATP6V1B1 | 853 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| ATP9A | 13540 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| ATP9A | 13540 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| ATP9B | 13541 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| ATRNL1 | 29063 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ATRX | 886 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ATXN10 | 10549 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| AURKA | 11393 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0032 | 29221160 |
| AURKB | 11390 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| AURKB8 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| AWAT2 | 23251 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| AZGP1 | 910 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| B2M | 914 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| B3GALT4 | 919 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| B3GNT5 | 15684 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| BAALC | 14333 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| BACE2 | 934 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| BARX1 | 955 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| BARX2 | 956 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| BASP1 | 957 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| BBS9 | 30000 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0021 | 29221160 |
| BCAM | 6722 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| BCAS3 | 14347 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| BCAS4 | 14367 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| BCHE | 983 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| BCL11B | 13222 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| BCL6 | 1001 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| BEAN1 | 24160 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| BEND6 | 20871 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| BFSP1 | 1040 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| BHLHA15 | 22265 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| BHLHE40 | 1046 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| BHLHE41 | 16617 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| BICC1 | 19351 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| BICD1 | 1049 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| BICDL1 | 28095 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| BICDL1 | 28095 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| BICDL2 | 33584 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| BIRC3 | 591 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| BIRC51 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| BIRC6 | 13516 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| BLACAT1 | 48597 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| BLM | 1058 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| BLMH | 1059 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| BLNK | 14211 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| BMF | 24132 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| BMP1 | 1067 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| BMP5 | 1072 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| BMPER | 24154 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| BMPR2 | 1078 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| BNIPL | 16976 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| BOD1 | 25114 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| BOK | 1087 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| BPIFA1 | 15749 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| BPIFB1 | 16108 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| BPIFB1 | 16108 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19353633 |
| BRCC3 | 24185 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| BRD9 | 25818 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| BRINP2 | 13746 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| BRIP1 | 20473 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0021 | 29221160 |
| BRWD1 | 12760 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| BUB1 | 1148 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| BUB1B | 1149 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| C11ORF54 | 30204 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| C14orf132 | 20346 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| C15orf62 | 34489 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| C15orf65 | 44654 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| C17ORF63 | 25563 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| C1GALT1 | 24337 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| C1ORF112 | 25565 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| C1ORF54 | 26258 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| C1QTNF6 | 14343 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| C20orf204 | 27655 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| C20orf27 | 15873 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| C2CD4A | 33627 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| C2ORF49 | 28772 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| C3 | 1318 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| C3 | 1318 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 31501409 |
| C3ORF33 | 26434 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| C3ORF80 | 40048 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| C4BPA | 1325 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| C4BPB | 1328 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| C4BPB | 1328 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| C4ORF19 | 25618 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| C4ORF46 | 27320 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| C5AR1 | 1338 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| C6ORF141 | 21351 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| C6ORF15 | 13927 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| C8ORF88 | 44672 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| C9ORF152 | 31455 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CA2 | 1373 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| CA5B | 1378 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CA9 | 1383 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CAB39L | 20290 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CAB39L | 20290 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| CAB39L | 20290 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| CABLES1 | 25097 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CACFD1 | 1365 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CACNA1C | 1390 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CACNA1H | 1395 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CACNB2 | 1402 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CACNB4 | 1404 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CADM1 | 5951 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| CADPS | 1426 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CADPS2 | 16018 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CADPS2 | 16018 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| CALB2 | 1435 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| CALCR | 1440 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CALU | 1458 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| CAMK1D | 19341 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| CAMK1D | 19341 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| CAMK2B | 1461 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CAMP | 1472 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CANX | 1473 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| CANX | 1473 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| CANX | 1473 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| CAPN13 | 16663 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CAPN2 | 1479 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CAPN5 | 1482 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CAPN8 | 1485 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CAPS | 1487 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CARD10 | 16422 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CASK | 1497 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CASP14 | 1502 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CASP9 | 1511 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| CAST | 1515 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CAST | 1515 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CAST | 1515 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| CASZ1 | 26002 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CBFA2T2 | 1536 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0021 | 29221160 |
| CBFA2T2 | 1536 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| CBFA2T3 | 1537 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CCDC146 | 29296 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CCDC159 | 26996 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CCDC71 | 25760 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| CCDC74A | 25197 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CCDC85A | 29400 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CCDC89 | 26762 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CCDC9B | 33488 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CCL22 | 10621 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CCL5 | 10632 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| CCN5 | 12770 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CCN5 | 12770 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CCNG2 | 1593 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CCNT2 | 1600 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| CCPG1 | 24227 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| CCR1 | 1602 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CD109 | 21685 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| CD109 | 21685 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| CD36 | 1663 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CD58 | 1688 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| CD82 | 6210 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| CD99L2 | 18237 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| CDC14A | 1718 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CDC20 | 1723 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| CDC208 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CDC25A | 1725 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| CDC25C | 1727 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CDC25C7 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CDC42EP3 | 16943 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CDCA3 | 14624 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CDCA47 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CDCA7 | 14628 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| CDCA7L | 30777 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CDH10 | 1749 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| CDH12 | 1751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CDH26 | 15902 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| CDK14 | 8883 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CDK6 | 1777 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| CDKN1A | 1784 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| CDSN | 1802 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CDYL | 1811 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| CEACAM1 | 1814 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| CEACAM5 | 1817 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CEACAM6 | 1818 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| CEMIP | 29213 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| CENPA | 1851 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| CENPA2 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CENPE | 1856 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| CENPJ | 17272 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| CENPL | 17879 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CENPM | 18352 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CENPV | 29920 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CEP55 | 1161 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CEP95 | 25141 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| CFAP20DC | 24763 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CFAP44 | 25631 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CFAP58-DT | 45243 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CFAP92 | 29231 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CFD | 2771 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| CFL2 | 1875 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| CGA | 1885 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CGA | 1885 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| CGAS | 21367 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CGNL1 | 25931 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CGNL1 | 25931 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| CHAC1 | 28680 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| CHD1 | 1915 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| CHD4 | 1919 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CHI3L2 | 1933 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CHML | 1941 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CHN2 | 1944 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CHORDC1 | 14525 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| CHPF | 24291 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CHRM1 | 1950 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CHRNA5 | 1959 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CHST11 | 17422 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CHST3 | 1971 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| CILP | 1980 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CISH | 1984 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CITED1 | 1986 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CITED4 | 18696 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CKB | 1991 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| CKS1B | 19083 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CLCA2 | 2016 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CLCA2 | 2016 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| CLCN2 | 2020 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| CLCN3 | 2021 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| CLCN4 | 2022 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CLCN6 | 2024 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CLEC2B | 2053 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| CLEC3A | 2052 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CLEC3B | 11891 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CLEC7A | 14558 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CLIC3 | 2064 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CLMP | 24039 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CLSTN2 | 17448 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CLSTN3 | 18371 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CLTC | 2092 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| CLTCL1 | 2093 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| CLU | 2095 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| CMSS1 | 28666 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| CMTM8 | 19179 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CMYA5 | 14305 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CNFN | 30183 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CNGA1 | 2148 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CNKSR3 | 23034 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CNN2 | 2156 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| CNOT2 | 7878 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| CNTNAP2 | 13830 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| COG6 | 18621 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| COL12A1 | 2188 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| COL14A1 | 2191 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| COL16A1 | 2193 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| COL17A1 | 2194 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| COL18A1 | 2195 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| COL3A1 | 2201 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| COL4A4 | 2206 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| COL4A5 | 2207 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| COL4A5 | 2207 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| COL4A6 | 2208 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| COL5A1 | 2209 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| COL6A6 | 27023 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| COL9A3 | 2219 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| COLEC10 | 2220 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| COPS5 | 2240 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29511337 |
| COQ10B | 25819 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| CPA3 | 2298 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CPA4 | 15740 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| CPAMD8 | 23228 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CPD | 2301 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| CPE | 2303 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| CPEB2 | 21745 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CPEB4 | 21747 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CPEB4 | 21747 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| CPNE4 | 2317 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CPNE7 | 2320 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CPPED1 | 25632 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| CPS1 | 2323 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| CPZ | 2333 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CRABP1 | 2338 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CRACR2B | 28703 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CRAT | 2342 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CRBN | 30185 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| CREB3L1 | 18856 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| CREG2 | 14272 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| CRELD1 | 14630 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CRIP1 | 2360 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| CRISP3 | 16904 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CRNDE | 37078 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CRYZL1 | 2420 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CRYZL1 | 2420 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CSDE1 | 29905 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| CSGALNACT1 | 24290 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| CSN2 | 2447 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CSN3 | 2446 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CSPG4 | 2466 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| CTDSP2 | 17077 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| CTDSPL | 16890 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CTSC | 2528 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CTSF | 2531 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CTSL | 2537 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| CTSO | 2542 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CTSV | 2538 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CTSZ | 2547 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| CWC22 | 29322 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| CXADR | 2559 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CXCL119 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CXCL12 | 10672 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| CXCL1210 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| CXCL14 | 10640 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CXCL17 | 19232 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CXCL2 | 4603 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 31501409 |
| CXCR1 | 6026 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CXXC5 | 26943 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| CYB561 | 2571 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| CYBRD1 | 20797 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CYP1A1 | 2595 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CYP1A1 | 2595 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| CYP1B1 | 2597 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| CYP24A1 | 2602 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| CYP2C8 | 2622 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CYP2J2 | 2634 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CYP46A1 | 2641 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CYP4B1 | 2644 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CYP4F11 | 13265 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CYP4F12 | 18857 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| CYP4F22 | 26820 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| CYP4F3 | 2646 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CYP4V2 | 23198 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| CYP4Z2P | 24426 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| CYP51A1 | 2649 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| CYSRT1 | 30529 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| DAAM2 | 18143 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DAB2 | 2662 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| DAB2 | 2662 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| DAP | 2672 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DARS2 | 25538 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DBP | 2697 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DCAF13 | 24535 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| DCDC2 | 18141 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| DCLK1 | 2700 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0159 | 34680485 |
| DCTPP1 | 28777 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| DCUN1D4 | 28998 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| DDAH1 | 2715 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| DDIAS | 26351 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DDR2 | 2731 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| DDX31 | 16715 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| DDX58 | 19102 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| DEDD2 | 24450 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| DEGS2 | 20113 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DENND1B | 28404 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| DENND2B | 11350 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| DENND2B | 11350 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| DENND2B | 11350 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| DENND2C | 24748 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| DEPP1 | 23355 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| DGAT2 | 16940 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| DGAT2 | 16940 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| DHCR24 | 2859 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| DHCR7 | 2860 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| DHCR7 | 2860 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| DHRS2 | 18349 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| DHX57 | 20086 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DIO2 | 2884 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| DIPK1A | 32213 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| DIRAS2 | 19323 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DJ434O11 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| DKK1 | 2891 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| DLC1 | 2897 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| DLC1 | 2897 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 17911267 |
| DLG3 | 2902 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| DLG5 | 2904 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| DLGAP5 | 16864 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| DLL1 | 2908 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| DLX3 | 2916 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| DLX3 | 2916 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| DMACs2L | 18799 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| DMD | 2928 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| DMKN | 25063 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| DMP1 | 2932 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DMRT2 | 2935 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DMRTA1 | 13826 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DNA2 | 2939 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| DNAJA1 | 5229 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| DNAJC10 | 24637 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| DNAJC12 | 28908 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| DNAJC12 | 28908 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| DNAJC4 | 5271 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DNASE1L2 | 2958 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DNER | 24456 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| DNHD1 | 26532 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DNM3 | 29125 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DNMBP | 30373 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| DNMT3B | 2979 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DOCK10 | 23479 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| DOCK5 | 23476 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| DOCK8 | 19191 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| DOK1 | 2990 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DOK7 | 26594 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DPF3 | 17427 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DPP4 | 3009 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0085 | 34680485 |
| DPY19L2P1 | 22305 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DRD1 | 3020 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DSC2 | 3036 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| DSCAM | 3039 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DSCAM-AS1 | 40197 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| DSCR1 | 3040 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| DSCR8 | 16707 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| DSG1 | 3048 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DSP | 3052 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19353633 |
| DST | 1090 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| DST | 1090 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| DTX4 | 29151 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| DTX4 | 29151 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| DUSP13 | 19681 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| DUSP2 | 3068 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| DUSP4 | 3070 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| DUSP4 | 3070 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| DUSP5 | 3071 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| DUSP5 | 3071 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| DUSP6 | 3072 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| DUSP6 | 3072 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 19353633 |
| DUSP6 | 3072 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| DUSP9 | 3076 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| DYNC2H1 | 2962 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| DYSF | 3097 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| DYX1C1 | 21493 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| EBP | 3133 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| ECEL1 | 3147 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ECHDC3 | 23489 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| ECHDC3 | 23489 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| ECM1 | 3153 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| EDN1 | 3176 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| EEF1A1 | 3189 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| EEF1A23 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| EEF1B2 | 3208 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| EEF1D | 3211 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| EEF1D | 3211 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| EEF2 | 3214 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| EEF2 | 3214 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| EFCC1 | 25692 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| EFHD2 | 28670 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| EFR3A | 28970 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| EGR1 | 3238 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 34680485 |
| EGR1 | 3238 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 31501409 |
| EGR2 | 3239 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| EGR3 | 3240 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| EHD1 | 3242 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| EHD2 | 3243 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| EHF | 3246 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| EIF4A1 | 3282 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| EIF4A1 | 3282 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| EIF4A1 | 3282 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| EIF4A2 | 3284 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| EIF4EBP1 | 3288 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| EIF4G2 | 3297 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| EIF4G2 | 3297 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| EIF4G2 | 3297 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| EIF4G3 | 3298 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| EIF4G3 | 3298 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| EIF5A | 3300 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| ELAPOR1 | 29618 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| ELF3 | 3318 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| ELF5 | 3320 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ELL2 | 17064 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ELOVL2 | 14416 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| EMC10 | 27609 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| EML6 | 35412 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ENO1 | 3350 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0095 | 34680485 |
| ENO3 | 3354 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ENOPH1 | 24599 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| ENTPD2 | 3364 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ENTPD8 | 24860 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| EPB41L1 | 3378 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| EPB41L4A | 13278 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| EPC1 | 19876 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| EPC1 | 19876 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| EPDR1 | 17572 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| EPGN | 17470 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| EPGN | 17470 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| EPHA5 | 3389 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| EPHB3 | 3394 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| EPHB4 | 3395 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| EPHB6 | 3396 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| EPHX1 | 3401 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| EPPK1 | 15577 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| EPS15L1 | 24634 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| EPS15L1 | 24634 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ERI1 | 23994 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ERICH1 | 27234 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| ERLEC1 | 25222 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ERRFI1 | 18185 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ERV3-1 | 3454 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ERVMER34-1 | 42970 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ESCO2 | 27230 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| ESF1 | 15898 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| ESPN | 13281 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ESRRG | 3474 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ETFA | 3481 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0021 | 29221160 |
| ETV5 | 3494 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ETV5 | 3494 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ETV6 | 3495 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| EVA1C | 13239 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| EXO1 | 3511 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| EXOSC5 | 24662 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| EYA2 | 3520 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| F11R | 14685 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| FAAH2 | 26440 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| FABP5 | 3560 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| FADS3 | 3576 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| FAHD2B | 25318 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| FAHD2CP | 44135 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| FAIM | 18703 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| FAIM2 | 17067 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FAM107B | 23726 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FAM110B | 28587 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FAM120A | 13247 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| FAM124A | 26413 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FAM133B | 28629 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| FAM133B | 28629 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| FAM13A | 19367 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FAM171A1 | 23522 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FAM189A1 | 29075 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FAM214B | 25666 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| FAM216A | 30180 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| FAM49B | 25216 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| FAM64A | 25483 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| FAM83A | 28210 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FAM83D | 16122 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| FAM83E | 25972 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FASN | 3594 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 31501409 |
| FAT4 | 23109 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| FBL | 3599 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| FBLN2 | 3601 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| FBN1 | 3603 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| FBN1 | 3603 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| FBXL12 | 13611 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| FBXO2 | 13581 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| FDFT1 | 3629 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| FER1L4 | 15801 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FERMT1 | 15889 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| FERMT1 | 15889 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| FFAR2 | 4501 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FGD3 | 16027 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| FGD4 | 19125 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| FGF12 | 3668 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FGF13 | 3670 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FGFBP1 | 19695 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| FGFBP1 | 19695 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| FGFR1 | 3688 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| FHL2 | 3703 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| FHOD3 | 26178 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| FIGN | 13285 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| FKBP14 | 18625 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| FKBP2 | 3718 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FKBP4 | 3720 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| FKBP5 | 3721 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19353633 |
| FKBP5 | 3721 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| FLJ23867 | 17997 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FLJ25865 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| FLJ46875 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FLNA | 3754 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| FLNA | 3754 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| FLRT3 | 3762 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| FLRT3 | 3762 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| FMO5 | 3773 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FNDC3B | 24670 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| FOLR1 | 3791 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| FOXI1 | 3815 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FOXI3 | 35123 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FOXM17 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| FOXN2 | 5281 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| FOXO1 | 3819 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| FOXO4 | 7139 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FOXP110 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| FPGS | 3824 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| FREM2 | 25396 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| FRMD4B | 24886 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| FRMD5 | 28214 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| FRMD8 | 25462 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| FRY | 20367 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FRZB | 3959 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FSD1 | 13745 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| FSIP2 | 21675 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FST | 3971 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| FST | 3971 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| FSTL3 | 3973 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| FSTL3 | 3973 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| FSTL4 | 21389 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FTL | 3999 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| FTO | 24678 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| FUBP1 | 4004 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 17911267 |
| FUT1 | 4012 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| FUT9 | 4020 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| FXYD4 | 4028 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| FZD4 | 4042 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| FZD6 | 4044 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| FZD7 | 4045 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| FZD8 | 4046 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GABPB1 | 4074 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| GABRP | 4089 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| GACAT2 | 50516 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GADD45B | 4096 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GADD45G9 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| GAL | 4114 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| GAL3ST2 | 24869 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GALM | 24063 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| GALNT12 | 19877 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| GALNT6 | 4128 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| GALNT6 | 4128 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| GALNT7 | 4129 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GALNT7 | 4129 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| GALNT79 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| GAPVD1 | 23375 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| GAS8-AS1 | 1197 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GASK1B | 25312 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| GATM | 4175 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| GBP2 | 4183 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GCHFR | 4194 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GCNT1 | 4203 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| GDF159 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| GDF7 | 4222 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GDPD1 | 20883 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GDPD3 | 28638 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GDPD5 | 28804 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GFOD1 | 21096 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GFPT2 | 4242 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| GFRA1 | 4243 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GGT1 | 4250 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GGT5 | 4260 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GGT6 | 26891 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GGT7 | 4259 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GINS4 | 28226 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| GJA1 | 4274 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| GJA1 | 4274 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19353633 |
| GJB1 | 4283 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19353633 |
| GLA | 4296 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GLDN | 29514 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GLRX | 4330 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| GMIP | 24852 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| GMPR | 4376 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GNAI1 | 4384 | HTM | Luminal A Breast Cancer | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 | |
| GNAO1 | 4389 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GNAS | 4392 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| GNE | 23657 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| GNG4 | 4407 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GNPTAB | 29670 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| GOLGA2P5 | 25315 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| GOLGA4 | 4427 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| GOLT1B | 20175 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| GPATCH2 | 25499 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| GPBP1L1 | 28843 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| GPC3 | 4451 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| GPC4 | 4452 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GPC6 | 4454 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GPD1 | 4455 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GPER1 | 4485 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GPNMB6 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| GPR143 | 20145 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GPR160 | 23693 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GPR180 | 28899 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| GPR3 | 4484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| GPR37L1 | 14923 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GPR68 | 4519 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| GPRC5A | 9836 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| GPRIN3 | 27733 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GPX1 | 4553 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| GPX8 | 33100 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| GRAMD1A | 29305 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| GRAMD2B | 24911 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| GRB14 | 4565 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GREB1 | 24885 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GREM1 | 2001 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| GREP1 | 27549 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GRIK2 | 4580 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| GRIK3 | 4581 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GRK5 | 4544 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| GSDMC | 7151 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GSN | 4620 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| GSTA1 | 4626 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| GSTA2 | 4627 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| GSTM1 | 4632 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GSTM3 | 4635 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| GTSE13 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| GUCY1A2 | 4684 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| GUCY1B1 | 4687 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| GULP1 | 18649 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| GYMAP7 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| H1-2 | 4716 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| H19 | 4713 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 34680485 |
| H19 | 4713 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 31501409 |
| H195 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| H2AC15 | 4726 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H2AC8 | 4724 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| H2ACP1 | 42647 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H2ACP1 | 42647 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H2ACP1 | 42647 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H2ACP1 | 42647 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H2ACP1 | 42647 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H2ACP1 | 42647 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H2AFY2 | 14453 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| H2BC21 | 4760 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| H2BC3 | 4751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H2BC3 | 4751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H2BC3 | 4751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H2BC3 | 4751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H2BC3 | 4751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H2BC3 | 4751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H2BC8 | 4746 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| H3-4 | 4778 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H3C10 | 4775 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H3C2 | 4776 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H3C7 | 4773 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| H3C8 | 4772 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H4C14 | 4794 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| H4C5 | 4790 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H4C8 | 4788 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| H4C8 | 4788 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| H4C9 | 4793 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| H4C9 | 4793 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| HAR1A | 33117 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| HAR1B | 33118 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| HAS3 | 4820 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| HAT1 | 4821 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0021 | 29221160 |
| HAUS1 | 25174 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HAUS6 | 25948 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HBA2 | 4824 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| HBP110 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| HCK | 4840 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| HCMOG | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| HDAC11 | 19086 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HDAC9 | 14065 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HDAC9 | 14065 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| HDGF | 4856 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| HDLBP | 4857 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| HEATR5A | 20276 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| HECW2 | 29853 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| HECW2 | 29853 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| HEG1 | 29227 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| HEG1 | 29227 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| HERC1 | 4867 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| HERC3 | 4876 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| HERC4 | 24521 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29511337 |
| HERC4 | 24521 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| HES1 | 5192 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 31501409 |
| HEY2 | 4881 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HFE | 4886 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| HHIPL2 | 25842 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| HILPDA | 28859 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| HIST1H4J | 4788 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| HIVEP1 | 4920 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| HK1 | 4922 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| HLA-DQB1 | 4944 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| HLA-DRB1 | 4948 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HLA-DRB5 | 4953 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| HMGB2 | 5000 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| HMGCLL1 | 21359 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| HMGCR | 5006 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| HMGCS1 | 5007 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 34680485 |
| HMGCS1 | 5007 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 31501409 |
| HMGCS1 | 5007 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 31501409 |
| HMGN5 | 8013 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| HNMT | 5028 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HNRNPA2B1 | 5033 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| HNRNPC | 5035 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| HNRNPC | 5035 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| HNRNPH1 | 5041 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| HNRNPH1 | 5041 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| HNRNPH1 | 5041 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| HNRNPH1 | 5041 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| HNRNPU | 5048 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| HOOK1 | 19884 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| HOPX | 24961 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| HOXC13 | 5125 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| HPD | 5147 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| HPGD | 5154 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| HPRT1 | 5157 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| HPS5 | 17022 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| HPSE | 5164 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| HR | 5172 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| HROB | 28460 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| HS3ST3A1 | 5196 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| HS3ST6 | 14178 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| HS6ST3 | 19134 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| HSD17B14 | 23238 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| HSD3B1 | 5217 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| HSH2D | 24920 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| HSP90AB1 | 5258 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 31501409 |
| HSPA1A | 5232 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| HSPA1A | 5232 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| HSPA1B | 5233 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| HSPA1L | 5234 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| HSPA2 | 5235 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| HSPA8 | 5241 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 31501409 |
| HSPBAP1 | 16389 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| HSPD1 | 5261 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 31501409 |
| HSPG2 | 5273 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HSPH1 | 16969 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| HSPH1 | 16969 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| HUWE1 | 30892 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 29511337 |
| HYKK | 34403 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| HYPK | 18418 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ICAM1 | 5344 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| ID1 | 5360 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| ID1 | 5360 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 19353633 |
| ID2 | 5361 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 34680485 |
| ID2 | 5361 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 31501409 |
| ID3 | 5362 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| ID3 | 5362 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| ID35 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| IDI1 | 5387 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| IER3 | 5392 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| IER3 | 5392 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| IER5 | 5393 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| IER5 | 5393 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| IER5L | 23679 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| IFI30 | 5398 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| IFI44L | 17817 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| IFITM1 | 5412 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| IFITM10 | 40022 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| IFITM3 | 5414 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| IFNL1 | 18363 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IFRD2 | 5457 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| IFT122 | 13556 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IGFBP2 | 5471 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| IGFBP3 | 5472 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0095 | 34680485 |
| IGFBP4 | 5473 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| IGFBP46 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| IGFBP5 | 5474 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| IGFBP52 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| IGFL1 | 24093 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IGFL2-AS1 | 52559 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IGSF1 | 5948 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| IGSF10 | 26384 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IGSF3 | 5950 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| IL17RC | 18358 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IL17RE | 18439 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IL17REL | 33808 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IL18R1 | 5988 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IL20RA | 6003 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IL7R | 6024 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| INAFM2 | 35165 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| INHA | 6065 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| INHBA | 6066 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 17911267 |
| INPP4B | 6075 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| INPP5A | 6076 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| INSIG1 | 6083 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| INTS6 | 14879 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| IQSEC2 | 29059 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| IRAK2 | 6113 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| IRX3 | 14360 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| IRX5 | 14361 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ISOC1 | 24254 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ITCH | 13890 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29511337 |
| ITGA1 | 6134 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ITGA10 | 6135 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ITGA2 | 6137 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0106 | 34680485 |
| ITGA2 | 6137 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 31501409 |
| ITGA2 | 6137 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 31501409 |
| ITGAE | 6147 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| ITGB6 | 6161 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ITGB8 | 6163 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| ITGB8 | 6163 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| ITM2C | 6175 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ITPK1 | 6177 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 17911267 |
| ITPR1 | 6180 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| ITPR2 | 6181 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| ITPRIP | 29370 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ITSN1 | 6183 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ITSN1 | 6183 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| JAK1 | 6190 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| JCAD | 29283 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| JDP2 | 17546 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| JMJD4 | 25724 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| JMJD7 | 34397 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| JPH2 | 14202 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| JPH2 | 14202 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| JPH3 | 14203 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KALRN | 4814 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| KAT2B | 8638 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| KAT6B | 17582 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| KAZALD1 | 25460 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KCNC1 | 6233 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KCND3 | 6239 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KCNF1 | 6246 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| KCNJ8 | 6269 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| KCNK13 | 6275 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KCNK3 | 6278 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KCNK5 | 6280 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KCNK59 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| KCNMA1 | 6284 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| KCNMB2 | 6286 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| KCNN4 | 6293 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KDELR3 | 6306 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KIAA0040 | 28950 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| KIAA0895L | 34408 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KIAA1549 | 22219 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KIF13A | 14566 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| KIF14 | 19181 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| KIF26A | 20226 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| KIFAP3 | 17060 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| KITLG | 6343 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KITLG | 6343 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| KLF10 | 11810 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| KLF3-AS1 | 25796 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KLF7 | 6350 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| KLF9 | 1123 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| KLHL13 | 22931 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| KLHL13 | 22931 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| KLK11 | 6359 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| KLK6 | 6367 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| KLRG2 | 24778 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KMT2C | 13726 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| KREMEN1 | 17550 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KREMEN1 | 17550 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| KREMEN2 | 18797 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KRT1 | 6412 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| KRT10 | 6413 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KRT13 | 6415 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KRT14 | 6416 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KRT15 | 6421 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| KRT16 | 6423 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| KRT16 | 6423 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| KRT17 | 6427 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| KRT17 | 6427 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| KRT17P2 | 6429 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| KRT23 | 6438 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| KRT3 | 6440 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KRT32 | 6449 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KRT34 | 6452 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| KRT38 | 6456 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| KRT4 | 6441 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| KRT5 | 6442 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| KRT6B | 6444 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| KRT6C | 20406 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| KRT7 | 6445 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| KRT79 | 28930 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KRT80 | 27056 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| KRT80 | 27056 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| KRT80 | 27056 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| KRT8P37 | 39871 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| KRT9 | 6447 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| KRTDAP | 16313 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| KTN1 | 6467 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| KYNU | 6469 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| LAMA3 | 6483 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| LAMB2 | 6487 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LAMB3 | 6490 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| LANCL1 | 6508 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| LBR | 6518 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LCA5 | 31923 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| LCMT2 | 17558 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| LCN2 | 6526 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| LCP1 | 6528 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| LDB1 | 6532 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| LDB3 | 15710 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LDHA | 6535 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| LDLRAD3 | 27046 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LGALS1 | 6561 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 19353633 |
| LGSN | 21016 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| LIF | 6596 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LIMA1 | 24636 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| LIMCH1 | 29191 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| LIMCH1 | 29191 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| LIMK2 | 6614 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LIN7A | 17787 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LINC00327 | 42009 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LINC00473 | 21160 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LINC00885 | 48571 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LINC00905 | 26334 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| LINC01016 | 48991 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| LINC01085 | 27198 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LINC01116 | 49259 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LINC01291 | 50358 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LINC01488 | 51144 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LINC01505 | 51186 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| LINC02395 | 53322 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LINC02551 | 53586 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| LINC02593 | 53933 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LINC02875 | 32699 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LIPG | 6623 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LMCD1 | 6633 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LMNB1 | 6637 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| LMNB2 | 6638 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| LMO1 | 6641 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| LMO1 | 6641 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| LMO3 | 6643 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LMO7 | 6646 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| LNX1 | 6657 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| LONRF2 | 24788 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LOXL3 | 13869 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LPAR1 | 3166 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| LPCAT1 | 25718 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LPIN1 | 13345 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LRAT | 6685 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| LRIG1 | 17360 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| LRIG3 | 30991 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LRP12 | 31708 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| LRP1B | 6693 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LRP5 | 6697 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| LRPPRC | 15714 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 17911267 |
| LRRC10B | 37215 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LRRC15 | 20818 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LRRC23 | 19138 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| LRRC4 | 15586 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LRRC61 | 21704 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| LRRC61 | 21704 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 19353633 |
| LRRC75B | 33155 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LSM11 | 30860 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LSM14A | 24489 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| LSM2 | 13940 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| LSM6 | 17017 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| LTBP2 | 6715 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LURAP1L | 31452 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| LURAP1L | 31452 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| LURAP1L | 31452 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| LURAP1L | 31452 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| LXN | 13347 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| LXN | 13347 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| LY6E | 6727 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| LY6G6C | 13936 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LYAR | 26021 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| LYAR | 26021 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| LYN | 6735 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| LYPD3 | 24880 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| LYPD3 | 24880 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| LYPD6B | 27018 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| LYPLAL1 | 20440 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| MACC1 | 30215 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MACROD2 | 16126 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MACsF1 | 13664 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MAD2L1 | 6763 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MAFB | 6408 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| MAFF | 6780 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MAGEA1 | 6796 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MALAT1 | 29665 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 34680485 |
| MALRD1 | 24331 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MAML2 | 16259 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MAN1A1 | 6821 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MAN2A110 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| MANSC1 | 25505 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| MANSC1 | 25505 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| MAOA | 6833 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MAP10 | 29265 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MAP1S | 15715 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| MAP2 | 6839 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MAP3K14 | 6853 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MAP3K20 | 17797 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| MAP4 | 6862 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MAP4K3 | 6865 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| MAP4K4 | 6866 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MAP7D2 | 25899 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| MAPK10 | 6872 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| MAPK11 | 6873 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MAPK13 | 6875 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| MAPK15 | 24667 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MAPK4 | 6878 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MAST4 | 19037 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MAST4 | 19037 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| MATK | 6906 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| MATN2 | 6908 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MATN3 | 6909 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MB21D2 | 30438 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| MBNL1 | 6923 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| MBNL1 | 6923 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| MBNL2 | 16746 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| MBOAT1 | 21579 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MCC | 6935 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| MCF2L | 14576 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MCFD2 | 18451 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MCM2 | 6944 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MCM59 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| MCM9 | 21484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| MDGA2 | 19835 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| MDH1 | 6970 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 17911267 |
| MDK | 6972 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MDM2 | 6973 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0042 | 29221160 |
| MDM2 | 6973 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 29511337 |
| ME1 | 6983 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 17911267 |
| MECOM | 3498 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MED13 | 22474 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| MED13L | 22962 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0032 | 29221160 |
| MED13L | 22962 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| MEIS1 | 7000 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| MELK | 16870 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MEST | 7028 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| METTL7A | 24550 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| METTL7A | 24550 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| MEX3A | 33482 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MFSD2A | 25897 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MFSD6 | 24711 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MGC26963 | 28395 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| MGC26963 | 28395 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| MGLL | 17038 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| MGLL | 17038 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| MGP | 7060 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MIA2 | 18432 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MIA3 | 24008 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MICA | 7090 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MICB | 7091 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MID1 | 7095 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MID2 | 7096 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MINAR1 | 29172 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| MIR103A1 | 31490 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR107 | 31496 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR122 | 31501 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 30188754 |
| MIR122 | 31501 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 30188754 |
| MIR1229 | 33924 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR1234 | 33926 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29187905 |
| MIR1234 | 33926 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30188754 |
| MIR1249 | 35315 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR1250 | 35316 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR1255A | 35320 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR125B1 | 31506 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29187905 |
| MIR1260B | 38258 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30188754 |
| MIR1262 | 35328 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR1273C | 38173 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR1276 | 35347 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR1277 | 35350 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR1285-1 | 35277 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR1285-1 | 35277 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR1285-1 | 35277 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR1285-1 | 35277 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR1291 | 35284 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR1306 | 35371 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR135B | 31760 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30188754 |
| MIR135B | 31760 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30188754 |
| MIR139 | 31526 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30188754 |
| MIR139 | 31526 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30188754 |
| MIR146A | 31533 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30188754 |
| MIR148A | 31535 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR148A | 31535 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR150 | 31537 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR151A | 31762 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29187905 |
| MIR15B | 31544 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0085 | 29187905 |
| MIR16-1 | 31545 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR181C | 31552 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30188754 |
| MIR181D | 32089 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30188754 |
| MIR1910 | 35394 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR193B | 32087 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR193B | 32087 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR19B1 | 31575 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29187905 |
| MIR200C | 31580 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 29187905 |
| MIR200C | 31580 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 30188754 |
| MIR202 | 32080 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR204 | 31582 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR204 | 31582 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR20A | 31577 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29187905 |
| MIR21 | 31586 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0085 | 29187905 |
| MIR211 | 31588 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR217 | 31594 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR221 | 31601 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 30188754 |
| MIR223 | 31603 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR224 | 31604 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 29187905 |
| MIR2278 | 37315 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR23B | 31606 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR23B | 31606 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30188754 |
| MIR23C | 38913 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30188754 |
| MIR24-1 | 31607 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR2467 | 41881 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR26B | 31612 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR27B | 31614 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29187905 |
| MIR29B1 | 31619 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 29187905 |
| MIR3065 | 38234 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR3065 | 38234 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR30A | 31624 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0085 | 29187905 |
| MIR3126 | 38225 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3130-1 | 38275 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR3155B | 50003 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3158-1 | 38196 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3158-1 | 38196 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3173 | 38174 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR3177 | 38364 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3187 | 38319 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR320B1 | 35247 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR320D1 | 35386 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR34A | 31635 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29187905 |
| MIR3609 | 38956 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3615 | 38905 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3615 | 38905 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR365A | 33692 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR3663 | 38958 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29187905 |
| MIR3679 | 38979 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR3688-1 | 38986 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR378B | 38283 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR379 | 31872 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR379 | 31872 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR381 | 31874 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3913-1 | 38884 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR3922 | 38895 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR3922 | 38895 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR3929 | 38945 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR3944 | 38898 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR409 | 32055 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR421 | 32793 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR421 | 32793 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR4435-1 | 41713 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR4443 | 41830 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29187905 |
| MIR4470 | 41833 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR4470 | 41833 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR4474 | 41821 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR4488 | 41599 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR449A | 27645 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR452 | 32054 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR4521 | 41813 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30188754 |
| MIR4530 | 41764 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29187905 |
| MIR4645 | 41689 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR4659A | 41857 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR4661 | 41582 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR4665 | 41696 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30188754 |
| MIR4676 | 41691 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR4728 | 41632 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR4731 | 41597 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR4791 | 41704 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR486-1 | 32342 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 30188754 |
| MIR486-1 | 32342 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 30188754 |
| MIR494 | 32084 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR499A | 32133 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR5000 | 43464 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR5010 | 43484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR516A1 | 32130 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR548AC | 41626 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR548Ad | 41683 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR548Ad | 41683 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR548Ah | 41605 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR548Ap | 43465 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR548AP | 43465 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR548l | 35292 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR548l | 35292 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR548y | 38980 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR548y | 38980 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR549A | 32803 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR5582 | 43461 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR573 | 32829 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR584 | 32840 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR584 | 32840 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR6087 | 50045 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR6088 | 50164 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR614 | 32870 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| MIR616 | 32872 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR627 | 32883 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR6501 | 50033 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR6505 | 50104 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR6511B1 | 50228 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR6733 | 50239 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR675 | 33351 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 30188754 |
| MIR6756 | 49974 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR6788 | 50078 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR6820 | 50095 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR708 | 33654 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR7-1 | 31638 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 30188754 |
| MIR7-1 | 31638 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 30188754 |
| MIR7110 | 50024 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30188754 |
| MIR7641-1 | 49995 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR7704 | 50089 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 30188754 |
| MIR7704 | 50089 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR7705 | 50143 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30188754 |
| MIR939 | 33682 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 30188754 |
| MIR9-3HG | 27388 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MIRLET7B | 31479 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 29187905 |
| MITF | 7105 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MLKL | 26617 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MLKL | 26617 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MLLT10 | 16063 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| MLLT11 | 16997 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MLXIP | 17055 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| MME | 7154 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| MN1 | 7180 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MOB4 | 17261 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| MON2 | 29177 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| MORN2 | 30166 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MOSMO | 27087 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| MPP2 | 7220 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MPP7 | 26542 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| MPZL2 | 3496 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| MPZL2 | 3496 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| MRPL11 | 14042 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MRPL51 | 14044 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| MRTFA | 14334 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MSANTD3 | 23370 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MSMB | 7372 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| MSMO1 | 10545 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MSTO2P | 26329 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MT1X | 7405 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| MT2A | 7406 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| MTHFD1L | 21055 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MT-ND1 | 7455 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| MTUS1 | 29789 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| MUC13 | 7511 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| MUC16 | 15582 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| MUC5B | 7516 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| MVD | 7529 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| MVP | 7531 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19353633 |
| MX2 | 7533 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MYADM | 7544 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| MYB | 7545 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MYBL2 | 7548 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| MYBL2 | 7548 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| MYBL21 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| MYCN | 7559 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| MYH14 | 23212 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MYLIP | 21155 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MYLPF | 29824 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| MYNN | 14955 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| MYO10 | 7593 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| MYO15B | 14083 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MYO1B | 7596 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| MYO5C | 7604 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| MYO7A | 7606 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| MYO9A | 7608 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| MYO9B | 7609 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| MYORG | 19918 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| MYPN | 23246 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| MYZAP | 43444 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| NABP1 | 26232 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| NABP1 | 26232 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| NABP2 | 28412 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| NAGK | 17174 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NAGS | 17996 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| NAMPT | 30092 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| NAPRT | 30450 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| NAT8L | 26742 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| NAV2 | 15997 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| NAV3 | 15998 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| NBPF1 | 26088 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| NCALD | 7655 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NCAPH | 1112 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| NCCRP1 | 33739 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| NCKAP5 | 29847 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NCS1 | 3953 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| NDC1 | 25525 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| NDRG1 | 7679 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 34680485 |
| NDRG19 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| NEAT1 | 30815 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NECAB1 | 20983 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| NEDD4 | 7727 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| NEDD4L | 7728 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| NEDD9 | 7733 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| NEFH | 7737 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| NELL2 | 7751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NETO1 | 13823 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| NEU1 | 7758 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| NEURL1 | 7761 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NEURL1B | 35422 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| NEXMIF | 29433 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NFASC | 29866 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NFIB | 7785 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| NFIX | 7788 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| NFKBIA | 7797 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| NHS | 7820 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NHSL2 | 33737 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NIBAN1 | 16784 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| NIBAN1 | 16784 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 19353633 |
| NIN | 14906 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NIPAL1 | 27194 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NKAIN1 | 25743 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| NKILA | 51599 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| NKX3-1 | 7838 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NLN | 16058 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| NLRC5 | 29933 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NME1 | 7849 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| NME2 | 7850 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| NOC3L | 24034 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| NOL10 | 25862 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| NOV | 7885 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NPC1 | 7897 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| NPNT | 27405 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| NPPA-AS1 | 37635 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NPTN | 17867 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| NR1H2 | 7965 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| NR3C1 | 7978 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| NR3C1 | 7978 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| NR3C1 | 7978 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| NR3C2 | 7979 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| NR4A1 | 7980 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| NR4A2 | 7981 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| NR4A2 | 7981 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| NR5A2 | 7984 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| NRAD1 | 26981 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| NRCAM | 7994 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| NRDC | 7995 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| NRIP1 | 8001 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| NRK | 25391 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NT5C2 | 8022 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| NT5E | 8021 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0095 | 34680485 |
| NT5E | 8021 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 31501409 |
| NT5E | 8021 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 17911267 |
| NTN1 | 8029 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| NTN4 | 13658 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| NTRK2 | 8032 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| NTSR1 | 8039 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NUCB2 | 8044 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| NUCB2 | 8044 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| NUP107 | 29914 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| NWD1 | 27619 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| NXNL2 | 30482 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| OAT | 8091 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ODC19 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| OIP58 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| OLA1 | 28833 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0021 | 29221160 |
| OLFM1 | 17187 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| OLFML2A | 27270 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| OLFML2A | 27270 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| OLFML3 | 24956 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| OLMALINC | 28060 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| OLR1 | 8133 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| OPLAH | 8149 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| OPN3 | 14007 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| OPRD1 | 8153 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| OR9A3P | 15094 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ORC1 | 8487 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ORC6L2 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| OSGIN1 | 30093 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| OTULINL | 25629 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| OTULINL | 25629 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| OVOL2 | 15804 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| OXGR1 | 4531 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| OXTR | 8529 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| P2RX3 | 8534 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| P2RY6 | 8543 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PABPC1 | 8554 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| PABPC1 | 8554 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| PABPC1L | 15797 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PABPC4L | 31955 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PADI2 | 18341 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PAG1 | 30043 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| PAG1 | 30043 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| PAGM5 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| PAICS | 8587 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| PALM3 | 33274 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PALMD | 15846 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| PAM | 8596 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PAN3 | 29991 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| PANK3 | 19365 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| PAPLN | 19262 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PAQR5 | 29645 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PAQR7 | 23146 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PARM1 | 24536 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PBXIP1 | 21199 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PC | 8636 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PCDH10 | 13404 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PCDH7 | 8659 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PCDH8 | 8660 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PCDH9 | 8661 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PCDHAC2 | 8677 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PCED1B | 28255 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PCK2 | 8725 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| PCSK1 | 8743 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PCSK2 | 8744 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PCSK9 | 20001 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| PDCD4 | 8763 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| PDE1A | 8774 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PDE1A | 8774 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| PDE3A | 8778 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| PDE3B | 8779 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| PDE4DIP | 15580 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| PDGFB | 8800 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| PDGFRL | 8805 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PDK3 | 8811 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PDK4 | 8812 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| PDLIM1 | 2067 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PDLIM5 | 17468 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| PDZD2 | 18486 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PDZD7 | 26257 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PEG13 | 19969 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PELI1 | 8827 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29511337 |
| PER3 | 8847 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| PERP | 17637 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PEX11A | 8852 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PFAS | 8863 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PFKFB3 | 8874 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PFKP | 8878 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PFN1 | 8881 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| PGLYRP2 | 30013 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PGM2L1 | 20898 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PHIP | 15673 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| PHLDA2 | 12385 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PHLDA2 | 12385 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| PHLDB1 | 23697 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PHOSPHO1 | 16815 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PI3 | 8947 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| PIEZO1 | 28993 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PIF1 | 26220 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| PIK3C2B | 8972 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| PIK3C2B | 8972 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| PIK3C3 | 8974 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| PIK3R1 | 8979 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| PIK3R1 | 8979 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 17911267 |
| PIK3R3 | 8981 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PIK3R5 | 30035 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PIM1 | 8986 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PIP | 8993 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| PIP4K2A | 8997 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PITPNM3 | 21043 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PJA2 | 17481 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| PKDCC | 25123 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| PKIB | 9018 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PKM | 9021 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| PKN1 | 9405 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PKNOX2 | 16714 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PKP1 | 9023 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PKP2 | 9024 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| PLA2G3 | 17934 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| PLA2G4C | 9037 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| PLA2G4F | 27396 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLA2R1 | 9042 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PLAAT3 | 17825 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| PLAAT3 | 17825 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| PLAT | 9051 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| PLAT | 9051 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| PLCB4 | 9059 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PLCD3 | 9061 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PLCH1 | 29185 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PLEC | 9069 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| PLEKHA2 | 14336 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| PLEKHA4 | 14339 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLEKHA5 | 30036 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| PLEKHB1 | 19079 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PLEKHG1 | 20884 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PLEKHG4 | 24501 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLEKHH2 | 30506 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PLIN2 | 248 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 34680485 |
| PLIN2 | 248 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| PLK13 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| PLK2 | 19699 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLK3 | 2154 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLLP | 18553 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLOD2 | 9082 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0074 | 34680485 |
| PLPP2 | 9230 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLPP3 | 9229 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLPPR2 | 29566 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLXNA3 | 9101 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PLXNB1 | 9103 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PLXNB3 | 9105 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PM20D2 | 21408 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PMEPA1 | 14107 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PNP | 7892 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PNPLA10P | 32928 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| PNPLA7 | 24768 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| POC1A | 24488 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| POC1B | 30836 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| POGLUT2 | 19350 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| POLR1E | 17631 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| POU2F3 | 19864 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| POU4F2 | 9219 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| PPARA | 9232 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| PPFIA4 | 9248 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PPFIBP1 | 9249 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PPFIBP2 | 9250 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| PPL | 9273 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| PPM1E | 19322 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PPM1L | 16381 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PPP1R1B | 9287 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PPP1R3C | 9293 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| PPP1R9B | 9298 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PRAG1 | 25438 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PRDX2 | 9353 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 31501409 |
| PRELID2 | 28306 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PRELID3B | 15892 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PREX1 | 32594 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| PREX1 | 32594 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 19353633 |
| PRICKLE2 | 20340 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PRICKLE2-AS1 | 40916 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PRKAB2 | 9379 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| PRKCD | 9399 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| PRLR | 9446 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PRODH | 9453 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PROSER2 | 23728 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| PRR11 | 25619 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| PRR15 | 22310 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PRRC2B | 28121 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| PRRT4 | 37280 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PRSS23 | 14370 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| PRSS56 | 39433 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PRSS56 | 39433 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PRTFDC1 | 23333 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| PSAPL1 | 33131 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PSCA | 9500 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| PSME3 | 9570 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29511337 |
| PSORS1C1 | 17202 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PSPC1 | 20320 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| PTGES | 9599 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PTGR1 | 18429 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| PTGS2 | 9605 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| PTK2B | 9612 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| PTMA | 9623 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| PTP4A2 | 9635 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| PTPLA9 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| PTPN14 | 9647 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| PTPN2 | 9650 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| PTPRN2 | 9677 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PTPRT | 9682 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PUDP | 16818 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| PUS1 | 15508 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PUS7 | 26033 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| PVT1 | 9709 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| PWWP2A | 29406 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| PXDN | 14966 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| PXMP4 | 15920 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| PZP | 9750 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| QARS1 | 9751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| QARS1 | 9751 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| QRICH2 | 25326 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| QSOX1 | 9756 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| RAB20 | 18260 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| RAB27A | 9766 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| RAB27B | 9767 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| RAB27B | 9767 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| RAB31 | 9771 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| RAB32 | 9772 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RAB3D | 9779 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RAB8B | 30273 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RABL2B | 9800 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| RACK1 | 4399 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| RAD51 | 9817 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 19353633 |
| RAD54B | 17228 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RAD54L | 9826 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RAET1L | 16798 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RAI14 | 14873 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RALGAPA1 | 17770 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| RALGAPB | 29221 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| RAMP3 | 9845 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RANBP3L | 26353 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| RAPGEFL1 | 17428 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| RAPH1 | 14436 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RARA | 9864 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RASAL2 | 9874 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| RASD1 | 15828 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RASGRP1 | 9878 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RASSF8 | 13232 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| RASSF8-AS1 | 48637 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RAVER2 | 25577 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| RBP7 | 30316 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| RBPMS | 19097 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| RCAN1 | 3040 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| RCC1 | 1913 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RCN3 | 21145 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| REG4 | 22977 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RELB | 9956 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| REPS2 | 9963 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RERG | 15980 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RETREG1 | 25964 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RFC2 | 9970 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| RGCC | 20369 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RGL1 | 30281 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RGS10 | 9992 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RGS2 | 9998 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| RGS6 | 10002 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RHBDD2 | 23082 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RHBDL3 | 16502 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RHBG | 14572 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RHCG | 18140 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| RHOBTB1 | 18738 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| RHOU | 17794 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| RHOV | 18313 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RHPN2 | 19974 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RIC8B | 25555 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| RIMKLA | 28725 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RIMS1 | 17282 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| RIMS2 | 17283 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RIMS3 | 21292 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| RIMS4 | 16183 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RIPK4 | 496 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RIPPLY3 | 3047 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RLN2 | 10027 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RMI2 | 28349 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RNASE4 | 10047 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| RNASE4 | 10047 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| RNASET2 | 21686 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RND3 | 671 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| RNF111 | 17384 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| RNF125 | 21150 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RNF128 | 21153 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RNF223 | 40020 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RNF224 | 41912 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RNF43 | 18505 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ROGDI | 29478 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| RORA | 10258 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RORC | 10260 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RP1 | 10263 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| RPAIN | 28641 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| RPF2 | 20870 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RPIA | 10297 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RPL12 | 10302 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RPL13A | 10304 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| RPL13A | 10304 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| RPL13A | 10304 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| RPL13A | 10304 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| RPL18A | 10311 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RPL23A | 10317 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| RPL23AP64 | 36552 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RPL32P31 | 37035 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| RPL37A | 10348 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| RPL9 | 10369 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| RPL9 | 10369 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| RPLP0 | 10371 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| RPRM | 24201 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RPS17 | 10397 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| RPS2 | 10404 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| RPS27A | 10417 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RPS29 | 10419 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RPS3 | 10420 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| RPS3A | 10421 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| RPS6KA5 | 10434 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RPS6KA5 | 10434 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| RPSA | 6502 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| RPSAP58 | 36809 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RPUSD3 | 28437 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RRAGD | 19903 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| RRAS | 10447 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| RRP7A | 24286 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| RSAD2 | 30908 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RSF1 | 18118 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| RSF1 | 18118 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| RSN | 10461 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| RTKN2 | 19364 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RTL5 | 29430 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RUBCNL | 20420 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| RUNDC3A | 16984 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RUNDC3A-AS1 | 51344 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RUNX1 | 10471 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| RUNX1T1 | 1535 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RUSC1-AS1 | 26680 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| RYR1 | 10483 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| S100A11 | 10488 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| S100A14 | 18901 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| S100A16 | 20441 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| S100A4 | 10494 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 34680485 |
| S100A4 | 10494 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 31501409 |
| S100A6 | 10496 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| S100A9 | 10499 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| S100P | 10504 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 19353633 |
| S100P | 10504 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0106 | 31501409 |
| SALL4 | 15924 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SAMD11 | 28706 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SAT1 | 10540 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| SAT1 | 10540 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 19353633 |
| SAT1 | 10540 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| SCARA3 | 19000 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SCARA3 | 19000 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| SCARA5 | 28701 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| SCARB1 | 1664 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SCCPDH | 24275 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SCD5 | 21088 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SCDP1 | 10572 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SCFD1 | 20726 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| SCG2 | 10575 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SCGB1A1 | 12523 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SCGB1D29 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| SCGB2A1 | 7051 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| SCIN | 21695 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| SCN1B | 10586 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SCNN1A | 10599 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| SCUBE2 | 30425 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SCYL3 | 19285 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| SDC2 | 10659 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| SEC14L1 | 10698 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SEC23A | 10701 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SEC31A | 17052 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SECISBP2L | 28997 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SECTM1 | 10707 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SELENBP1 | 10719 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SELENBP1 | 10719 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| SELENOM | 30397 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SELL | 10720 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SEMA3D | 10726 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SEMA4B | 10730 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SEMA4G | 10735 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SEMA5B | 10737 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SEMA6B | 10739 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SEMA6D | 16770 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SEMA7A | 10741 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| SENP3 | 17862 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SERHL2 | 29446 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SERINC1 | 13464 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| SERINC2 | 23231 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SERPINA1 | 8941 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SERPINB3 | 10569 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| SERPINB5 | 8949 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| SERPINB8 | 8952 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| SERPINE1 | 8583 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| SERPINE2 | 8951 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| SERPINE2 | 8951 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| SESN3 | 23060 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| SESTD1 | 18379 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SETD5 | 25566 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| SETSIP | 42937 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| SEZ6L2 | 30844 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SEZ6L2 | 30844 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| SFMBT2 | 20256 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| SFMBT2 | 20256 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| SFRS1810 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| SFRS3 | 10785 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| SFT2D1 | 21102 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SFXN2 | 16086 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SGCG | 10809 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SGK1 | 10810 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| SGPP1 | 17720 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SGPP2 | 19953 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SGSM1 | 29410 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SH3BGRL | 10823 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| SH3BGRL4 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| SH3BP2 | 10825 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SH3BP4 | 10826 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SH3BP4 | 10826 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| SH3BP5 | 10827 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SH3BP5-AS1 | 44501 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SH3PXD2A | 23664 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| SH3PXD2A | 23664 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| SH3PXD2B | 29242 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SH3TC2 | 29427 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SHANK2 | 14295 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SHC3 | 18181 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SHC4 | 16743 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SHCBP1 | 29547 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SHROOM3 | 30422 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SHROOM3 | 30422 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| SIDT1 | 25967 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SIGLEC15 | 27596 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SIK3 | 29165 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SIK3 | 29165 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| SIL1 | 24624 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SIMC1 | 24779 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SINHCAF | 30702 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| SIPA1L2 | 23800 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SIRT2 | 10886 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SKIL | 10897 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SKP2 | 10901 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| SLC12A1 | 10910 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC12A2 | 10911 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| SLC12A2 | 10911 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 19353633 |
| SLC12A4 | 10913 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC12A9 | 40807 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SLC16A2 | 10923 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SLC16A6 | 10927 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SLC17A5 | 10933 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SLC1A3 | 10941 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| SLC20A1 | 10946 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| SLC22A18 | 10964 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC22A4 | 10968 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC23A1 | 10974 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC25A18 | 10988 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC25A2 | 22921 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| SLC25A24 | 20662 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SLC25A29 | 20116 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC25A35 | 31921 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC25A45 | 27442 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC26A2 | 10994 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC26A6 | 14472 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SLC28A3 | 16484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC29A1 | 11003 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SLC29A3 | 23096 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SLC2A10 | 13444 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC2A14 | 18301 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SLC2A3 | 11007 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| SLC2A6 | 11011 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC34A3 | 20305 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC35C1 | 20197 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SLC35D2 | 20799 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SLC35F2 | 23615 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SLC37A2 | 20644 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC38A2 | 13448 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| SLC39A13 | 20859 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SLC39A6 | 18607 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC3A2 | 11026 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 31501409 |
| SLC44A2 | 17292 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| SLC44A3 | 28689 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC45A1 | 17939 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC4A8 | 11034 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC52A3 | 16187 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLC5A3 | 11038 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| SLC5A8 | 19119 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC6A12 | 11045 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| SLC7A5 | 11063 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| SLC7A8 | 11066 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SLC9A3R2 | 11076 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC9A4 | 11077 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLC9A7 | 17123 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLCO4A1 | 10953 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| SLCO4A1 | 10953 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| SLCO4C1 | 23612 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLIT1 | 11085 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SLIT2 | 11086 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SLITRK1 | 20297 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SLPI | 11092 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 34680485 |
| SLPI | 11092 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 31501409 |
| SMAD2 | 6768 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SMAD3 | 6769 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SMAD6 | 6772 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| SMAD7 | 6773 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| SMARCC1 | 11104 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| SMIM32 | 53640 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SMIM5 | 40030 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SMOC1 | 20318 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SMOC2 | 20323 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SMPD3 | 14240 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SNAPC1 | 11134 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| SNHG29 | 28619 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SNTB1 | 11168 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SNTB2 | 11169 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| SNX27 | 20073 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| SOCS2 | 19382 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| SOD2 | 11180 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| SOD2 | 11180 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 31501409 |
| SOGA1 | 16111 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| SON | 11183 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| SORCS1 | 16697 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SORCS2 | 16698 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SORD | 11184 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SORT1 | 11186 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| SOWAHC | 26149 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SOX13 | 11192 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SOX3 | 11200 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SOX9-AS1 | 49321 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SP6 | 14530 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SPATA18 | 29579 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SPATA20 | 26125 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SPATA9 | 22988 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SPATS2L | 24574 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SPC24 | 26913 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SPDEF | 17257 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SPHK1 | 11240 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SPHK2 | 18859 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SPINK4 | 16646 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SPIRE2 | 30623 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SPNS2 | 26992 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SPOCK1 | 11251 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| SPRR1A | 11259 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SPRR1B | 11260 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| SPRR2E | 11265 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| SPRY1 | 11269 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SPRY2 | 11270 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SPRY4 | 15533 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SPTLC3 | 16253 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| SPTLC3 | 16253 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| SPTSSA | 20361 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SPTY2D1 | 26818 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SQLE | 11279 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| SQSTM1 | 11280 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| SQSTM1 | 11280 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| SRCIN1 | 29506 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SRGAP3 | 19744 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SRGN | 9361 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| SRI | 11292 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SRMS | 11298 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SRP54 | 11301 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ST3GAL1 | 10862 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ST3GAL5 | 10872 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ST6GALNAC1 | 23614 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ST6GALNAC2 | 10867 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ST6GALNAC4 | 17846 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ST7 | 11351 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ST8SIA1 | 10869 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ST8SIA4 | 10871 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| ST8SIA6 | 23317 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| STARD4 | 18058 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| STARD4 | 18058 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| STAT4 | 11365 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| STC1 | 11373 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| STC1 | 11373 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| STEAP1 | 11378 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 19353633 |
| STMN3 | 15926 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| STOX2 | 25450 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| STRA6 | 30650 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| STUM | 30491 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SUCO | 1240 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| SULF2 | 20392 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SUSD2 | 30667 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SUSD3 | 28391 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| SUSD3 | 28391 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 19353633 |
| SVEP1 | 15985 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| SYBU | 26011 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SYCP2 | 11490 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| SYDE2 | 25841 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| SYN3 | 11496 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SYNGR1 | 11498 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| SYT10 | 19266 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SYT12 | 18381 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| SYT13 | 14962 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| SYT7 | 11514 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SYTL2 | 15585 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| SYTL2 | 15585 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| SYTL4 | 15588 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| SYTL5 | 15589 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TACC1 | 11522 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TAF13 | 11546 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TAF1D | 28759 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| TAF1D | 28759 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| TAF4B | 11538 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TAF4B | 11538 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| TAF5 | 11539 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TAOK3 | 18133 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| TARP | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TASOR2 | 23484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| TASOR2 | 23484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| TASOR2 | 23484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| TAZ | 11577 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| TBC1D15 | 25694 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| TBC1D30 | 29164 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| TBC1D9 | 21710 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TCAF2 | 26878 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TCF7 | 11639 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TCF7L1 | 11640 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| TCN1 | 11652 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TCOF1 | 11654 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| TCTA | 11692 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TDP2 | 17768 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| TEAD4 | 11717 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TECPR1 | 22214 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TENM3 | 29944 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| TENT2 | 26776 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| TENT5A | 18345 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TENT5C | 24712 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TESC | 26065 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TEX19 | 33802 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TFAP4 | 11745 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TFF3 | 11757 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| TFRC | 11763 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| TFRC | 11763 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| TGFA | 11765 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TGFB2-OT1 | 50629 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| TGFB3 | 11769 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TGFBI | 11771 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| TGIF2 | 15764 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| THAP5P1 | 22340 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| THBD | 11784 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| THEG | 13706 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| THEM5 | 26755 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| THOC2 | 19073 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| THOC5 | 19074 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| THSD4 | 25835 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| THYN1 | 29560 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TIAM1 | 11805 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TIMP1 | 11820 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| TIMP1 | 11820 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| TIMP1 | 11820 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| TIMP3 | 11822 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| TIMP3 | 11822 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| TIMP4 | 11823 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TJP2 | 11828 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| TK19 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| TLE2 | 11838 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TLE4 | 11840 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| TM7SF2 | 11863 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TMA16 | 25638 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TMC4 | 22998 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TMED3 | 28889 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TMEM104 | 25984 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TMEM123 | 30138 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TMEM126B | 30883 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| TMEM132D | 29411 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| TMEM138 | 26944 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| TMEM141 | 28211 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| TMEM150C | 37263 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TMEM158 | 30293 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| TMEM158 | 30293 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| TMEM181 | 20958 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| TMEM198 | 33704 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TMEM205 | 29631 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| TMEM229B | 20130 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TMEM258 | 1164 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TMEM44 | 25120 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TMEM45A | 25480 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| TMEM45B | 25194 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| TMEM489 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| TMEM64 | 25441 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TMEM79 | 28196 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TMEM87A | 24522 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| TMEM98 | 24529 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19353633 |
| TMPO8 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| TMPRSS11E | 24465 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TMPRSS4 | 11878 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| TMTC2 | 25440 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TNC | 5318 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| TNFAIP2 | 11895 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TNFAIP3 | 11896 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 34680485 |
| TNFAIP6 | 11898 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| TNFAIP8 | 17260 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TNFRSF10B | 11905 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TNFRSF10C | 11906 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TNFSF15 | 11931 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| TNFSF9 | 11939 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| TNIK | 30765 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 34680485 |
| TNIK | 30765 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 31501409 |
| TNRC6C-AS1 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TNS1 | 11973 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| TNS2 | 19737 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TNS2 | 19737 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| TNS3 | 21616 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| TNS4 | 24352 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| TOX3 | 11972 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| TP53 | 11998 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TP63 | 15979 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| TPBG | 12004 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| TPD52 | 12005 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TPD52 | 12005 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| TPD52L1 | 12006 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 34680485 |
| TPD52L110 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| TPM1 | 12010 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 31501409 |
| TPM4 | 12013 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| TPM4 | 12013 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 31501409 |
| TPX2 | 1249 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TRABD | 28805 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TRAF3IP2 | 1343 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TRAK1 | 29947 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TRAM2 | 16855 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| TRAP1 | 16264 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 34680485 |
| TRERF1 | 18273 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| TRIB1 | 16891 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TRIB2 | 30809 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TRIM16 | 17241 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| TRIM16L | 32670 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TRIM2 | 15974 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| TRIM2 | 15974 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| TRIM29 | 17274 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 34680485 |
| TRIM29 | 17274 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 31501409 |
| TRIM29 | 17274 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 31501409 |
| TRIM31 | 16289 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TRIM33 | 16290 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| TRIM5 | 16276 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| TRIML2 | 26378 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| TRIP13 | 12307 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| TRIP138 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| TRIP6 | 12311 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TRMT13 | 25502 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| TRNT1 | 17341 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0021 | 29221160 |
| TROAP8 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| TRPM7 | 17994 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| TRPV3 | 18084 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TSC22D3 | 3051 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| TSHZ2 | 13010 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| TSKU | 28850 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TSPAN1 | 20657 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| TSPAN12 | 21641 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TSPAN15 | 23298 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TSPAN2 | 20659 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TSPAN3 | 17752 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TSPAN3 | 17752 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| TSPEAR | 1268 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TSPEAR-AS1 | 1271 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TSPEAR-AS2 | 16428 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TSPYL2 | 24358 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| TSPYL2 | 24358 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| TTC17 | 25596 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TTC39C | 26595 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| TTC39C | 26595 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| TUBA1B | 18809 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19353633 |
| TUBA1B | 18809 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| TUBB6 | 20776 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| TUBG2 | 12419 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TUNAR | 44088 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TUSC3 | 30242 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TUT7 | 25817 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| TVP23B | 20399 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| TXLNB | 21617 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TXNDC16 | 19965 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19353633 |
| UBASH3B | 29884 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| UBC | 12468 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| UBE2C7 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| UBE2D1 | 12474 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| UBE2D3 | 12476 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29511337 |
| UBE2D3 | 12476 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| UBE2E1 | 12477 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| UBE2E3 | 12479 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| UBE2H | 12484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| UBE2H | 12484 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| UBE2QL1 | 37269 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| UBE2S8 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| UBE2T7 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| UBE3C | 16803 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| UCK2 | 12562 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| UGCG | 12524 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| UGG2 | 15664 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| UGT1A7 | 12539 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| UHRF2 | 12557 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| ULK1 | 12558 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| UMPK9 | NA | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19353633 |
| UNC13A | 23150 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| UNC13A | 23150 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| UNC13A | 23150 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| UNC13D | 23147 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| UNC13D | 23147 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| UPK1A | 12577 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| UPK2 | 12579 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| UPK3B | 21444 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| UQCC1 | 15891 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| URI1 | 13236 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| USP34 | 20066 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| USP53 | 29255 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| UTP25 | 28440 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| UVRAG | 12640 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| VAT1L | 29315 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| VGF | 12684 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| VGF | 12684 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 31501409 |
| VGLL3 | 24327 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| VHL | 12687 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| VILL | 30906 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| VIPR1 | 12694 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| VLDLR | 12698 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| VPS9D1 | 13526 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| VRK1 | 12718 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0011 | 29221160 |
| VSIG10L | 27111 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| VSIG2 | 17149 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| VTCN1 | 28873 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| VTN | 12724 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| VTN | 12724 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| VWA1 | 30910 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| VWA5B2 | 25144 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| VWA7 | 13939 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| WASF1 | 12732 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| WASF1 | 12732 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 19353633 |
| WBP2 | 12738 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| WDCP | 26157 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| WDCP | 26157 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| WDR12 | 14098 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| WDR20 | 19667 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| WDR31 | 21421 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| WDR45 | 28912 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| WFDC1 | 15466 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| WFDC2 | 15939 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 34680485 |
| WFDC21P | 50357 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| WIPF1 | 12736 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| WLS | 30238 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| WNK1 | 14540 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 31501409 |
| WNK1 | 14540 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 17911267 |
| WNT2B | 12781 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| WNT6 | 12785 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| WNT9A | 12778 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| WSCD1 | 29060 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| WWC2 | 24148 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| WWP2 | 16804 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| XAF1 | 30932 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| XG | 12806 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| XIAP | 592 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29511337 |
| XIST | 12810 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| XPO1 | 12825 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | NA | 0.04 | 0.0032 | 29221160 |
| YPEL2 | 18326 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| YWHAH | 12853 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| YWHAZ | 12855 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 31501409 |
| ZBED6CL | 21720 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZBTB2 | 20868 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ZBTB45 | 23715 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ZBTB7C | 31700 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ZC2HC1A | 24277 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 34680485 |
| ZC3H12A | 26259 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZC3H13 | 20368 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19353633 |
| ZDHHC3 | 18470 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZFAND3 | 18019 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| ZFC3H1 | 28328 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ZFHX3 | 777 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| ZFP1 | 23328 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| ZFP36 | 12862 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ZFX | 12869 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ZFYVE1 | 13180 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ZG16B | 30456 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZMAT1 | 29377 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZNF14 | 12924 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| ZNF165 | 12953 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ZNF185 | 12976 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 34680485 |
| ZNF215 | 13007 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ZNF222 | 13015 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZNF222 | 13015 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| ZNF26 | 13053 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| ZNF365 | 18194 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ZNF37BP | 13103 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ZNF420 | 20649 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ZNF436 | 20814 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZNF451 | 21091 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 31501409 |
| ZNF503 | 23589 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZNF503-AS2 | 23525 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ZNF529 | 29328 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| ZNF561 | 28684 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ZNF567 | 28696 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ZNF571 | 25000 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ZNF609 | 29003 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| ZNF618 | 29416 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ZNF619 | 26910 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ZNF638 | 17894 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19353633 |
| ZNF638 | 17894 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 17911267 |
| ZNF644 | 29222 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SP assay and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 17911267 |
| ZNF703 | 25883 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 34680485 |
| ZNF750 | 25843 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |
| ZNF804A | 21711 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ZNF831 | 16167 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 31501409 |
| ZNF841 | 27611 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ZNF852 | 27713 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ZNF853 | 21767 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| ZNF860 | 34513 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 34680485 |
| ZRSR2 | 23019 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 31501409 |
| ZSCAN2 | 20994 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 31501409 |
| ZSWIM8 | 23528 | HTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 34680485 |
| TNFRSF19 | 11915 | HTM/LTM | Luminal A Breast Cancer | Adenocarcinoma | MCF7 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 34680485 |